<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        48-82-08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GARDASIL RECOMBINANT VACCINE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HUMAN PAPILLOMAVIRUS TYPE 6 L1,HUMAN PAPILLOMAVIRUS TYPE 11 L1,HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN,HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20,40,40,20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        411.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MERCK SHARP AND DOHME LLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MERCK SHARP AND DOHME LLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SHARP & DOHME
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07BM 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gardasil is a vaccine. Vaccination with Gardasil is intended to protect against diseases caused by</p><p>Human Papillomavirus (HPV) types 6, 11, 16, and 18.</p><p>&nbsp;</p><p>These diseases include pre-cancerous lesions of the female genitals (cervix, vulva, and vagina); pre- cancerous lesions of the anus and genital warts in males and females; cervical and anal cancers. HPV types 16 and 18 are responsible for approximately 70% of cervical cancer cases, 75-80% of anal cancer cases; 70% of HPV-related pre-cancerous lesions of the vulva and vagina, 75% of HPV related pre-cancerous lesions of the anus. HPV types 6 and 11 are responsible for approximately 90% of genital wart cases.</p><p>&nbsp;</p><p>Gardasil is intended to prevent these diseases. The vaccine is not used to treat HPV related diseases. Gardasil does not have any effect in individuals who already have a persistent infection or disease associated with any of the HPV types in the vaccine. However, in individuals who are already infected with one or more of the vaccine HPV types, Gardasil can still protect against diseases associated with the other HPV types in the vaccine.</p><p>&nbsp;</p><p>Gardasil cannot cause the diseases it protects against.</p><p>&nbsp;</p><p>Gardasil produces type-specific antibodies and has been shown in clinical trials to prevent HPV 6-,</p><p>11-, 16-, and 18-related diseases in women 16-45 years of age and in men 16-26 years of age. The vaccine also produces type-specific antibodies in 9- to 15-year-old children and adolescents.</p><p>&nbsp;</p><p>Gardasil should be used in accordance with official guidelines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not receive Gardasil if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or your child is allergic (hypersensitive) to any of the active substances or any of the other ingredients of Gardasil (listed under &ldquo;other ingredients&rdquo;&ndash; see section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or your child developed an allergic reaction after receiving a dose of Gardasil.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or your child suffer from an illness with high fever. However, a mild fever or upper respiratory infection (for example cold) itself is not a reason to delay vaccination.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor, pharmacist or nurse before vaccination if you or your child</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has a bleeding disorder (a disease that makes you bleed more than normal), for example haemophilia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has a weakened immune system, for example due to a genetic defect, HIV infection or medicines that affect the immune system.</p><p>&nbsp;</p><p>Fainting, sometimes accompanied by falling, can occur (mostly in adolescents) following any needle injection. Therefore, tell the doctor or nurse if you fainted with a previous injection.</p><p>&nbsp;</p><p>As with any vaccine, Gardasil may not fully protect 100 % of those who get the vaccine.</p><p>&nbsp;</p><p>Gardasil will not protect against every type of Human Papillomavirus. Therefore, appropriate precautions against sexually transmitted disease should continue to be used.</p><p>&nbsp;</p><p>Gardasil will not protect against other diseases that are not caused by Human Papillomavirus.</p><p>&nbsp;</p><p>Vaccination is not a substitute for routine cervical screening<strong><em>. </em></strong>You should continue to follow your doctor&rsquo;s advice on cervical smear/Pap tests and preventative and protective measures.</p><p>&nbsp;</p><p><em>What other important information should you or your child know about Gardasil</em></p><p><em>&nbsp;</em></p><p>Longer term follow-up studies were conducted to determine the duration of protection. The need for a booster dose has not been established.</p><p>&nbsp;</p><p>Other medicines or vaccines and Gardasil</p><p>Gardasil can be given with a Hepatitis B vaccine or with a combined booster vaccine containing diphtheria (d) and tetanus (T) with either pertussis [acellular, component] (ap) and/or poliomyelitis [inactivated] (IPV) (dTap, dT-IPV, dTap-IPV vaccines) at a separate injection site (another part of your body, e.g. the other arm or leg) during the same visit.</p><p>&nbsp;</p><p>Gardasil may not have an optimal effect if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; used with medicines that suppress the immune system.</p><p>&nbsp;</p><p>In clinical trials, oral or other contraceptives (e.g. the pill) did not reduce the protection obtained by Gardasil.</p><p>&nbsp;</p><p>Please tell your doctor or pharmacist if you or your child are taking or have taken recently any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p>Pregnancy, breast-feeding and fertility</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>Gardasil may be given to women who are breast-feeding or intend to breast-feed.</p><p>&nbsp;</p><p>Driving and using machines</p><p>No studies on the effects on the ability to drive and use machines have been performed.</p><p>&nbsp;</p><p>Gardasil contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gardasil is given as an injection by your doctor. Gardasil is intended for adolescents and adults from</p><p>9 years of age onwards.</p><p><strong><em><u>If you are from 9 to and including 13 years of age</u></em></strong></p><p>Gardasil can be administered according to a 2-dose schedule:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First injection: at chosen date</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second injection: 6 months after first injection</p><p>If the second vaccine dose is administered earlier than 6 months after the first dose, a third dose should always be administered.</p><p>&nbsp;</p><p>Alternatively, Gardasil can be administered according to a 3-dose schedule:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First injection: at chosen date</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second injection: 2 months after first injection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Third injection: 6 months after first injection</p><p>The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose. All three doses should be given within a 1-year period. Please speak to your doctor for more information.</p><p>&nbsp;</p><p><strong><em><u>If you are from 14 years of age</u></em></strong></p><p>Gardasil should be administered according to a 3-dose schedule:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First injection: at chosen date</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second injection: 2 months after first injection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Third injection: 6 months after first injection</p><p>The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose. All three doses should be given within a 1-year period. Please speak to your doctor for more information.</p><p>&nbsp;</p><p>It is recommended that individuals who receive a first dose of Gardasil complete the vaccination course with Gardasil.</p><p>&nbsp;</p><p>Gardasil will be given as an injection through the skin into the muscle (preferably the muscle of the upper arm or thigh).</p><p>&nbsp;</p><p>The vaccine should not be mixed in the same syringe with any other vaccines and solutions.</p><p>&nbsp;</p><p><strong>I</strong><strong>f you forget one dose of Gardasil:</strong></p><p>&nbsp;</p><p>If you miss a scheduled injection, your doctor will decide when to give the missed dose.</p><p>It is important that you follow the instructions of your doctor or nurse regarding return visits for the follow-up doses. If you forget or are not able to go back to your doctor at the scheduled time, ask your</p><p>doctor for advice. When Gardasil is given as your first dose, the completion of the vaccination course should be done with Gardasil, and not with another HPV vaccine.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist<strong>.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all vaccines, this vaccine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The following side effects can be seen after the use of Gardasil:</p><p>&nbsp;</p><p><strong>Very common</strong> (may affect more than 1 in 10&nbsp;people), side effects found at the injection site include: pain, swelling and redness. Headache was also seen.</p><p>&nbsp;</p><p><strong>Common</strong> (may affect more than 1 in 100&nbsp;people), side effects found at the injection site include: bruising, itching, pain in extremity. Fever and nausea have also been reported.</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in&nbsp;100&nbsp;people): lump (nodule) at the injection site.</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect less than 1 in 1,000&nbsp;people): hives (urticaria).</p><p>&nbsp;</p><p><strong>Very rare</strong> (may affect less than 1 in 10,000&nbsp;people), difficulty breathing (bronchospasm) has been reported.</p><p>&nbsp;</p><p>When Gardasil was given with a combined diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] booster vaccine during the same visit, there was more headache and injection-site swelling.</p><p>&nbsp;</p><p><em>Side effects that have been reported during marketed use include:</em></p><p><em>&nbsp;</em></p><p>Fainting, sometimes accompanied by shaking or stiffening, has been reported. Although fainting episodes are uncommon, patients should be observed for 15 minutes after they receive HPV vaccine.</p><p>&nbsp;</p><p>Allergic reactions that may include difficulty breathing, wheezing (bronchospasm), hives and rash have been reported. Some of these reactions have been severe.</p><p>&nbsp;</p><p>As with other vaccines, side effects that have been reported during general use include: swollen glands (neck, armpit, or groin); muscle weakness, abnormal sensations, tingling in the arms, legs and upper body, or confusion (Guillain-Barr&eacute; Syndrome, Acute disseminated encephalomyelitis); dizziness, vomiting, joint pain, aching muscles, unusual tiredness or weakness, chills, generally feeling unwell, bleeding or bruising more easily than normal, and skin infection at the injection site.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance Centre (NPC)ز By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this vaccine out of the sight and reach of children.</p><p>Do not use this vaccine after the expiry date which is stated on the syringe label and the outer carton</p><p>(after EXP).</p><p>Store in a refrigerator (2&ordm;C - 8&ordm;C).</p><p>Do not freeze.</p><p>Keep the syringe in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are: highly purified non-infectious protein for each of the Human</p><p>Papillomavirus types (6, 11, 16, and 18).</p><p>&nbsp;</p><p>1 dose (0.5 ml) contains approximately:</p><p>&nbsp;</p><p>Human Papillomavirus1 Type 6 L1 protein2,3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20 micrograms Human Papillomavirus1 Type 11 L1 protein2,3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;40 micrograms Human Papillomavirus1 Type 16 L1 protein2,3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;40 micrograms Human Papillomavirus1 Type 18 L1 protein2,3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;20 micrograms</p><p>&nbsp;</p><p>1Human Papillomavirus = HPV</p><p>2L1 protein in the form of virus like particles produced in yeast cells (<em>Saccharomyces cerevisiae</em></p><p>CANADE 3C-5 (Strain 1895)) by recombinant DNA technology.</p><p>3adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.225 milligrams Al).</p><p>The other ingredients in the vaccine suspension are:</p><p>Sodium chloride (9.56 mg)</p><p>L-histidine (0.78 mg)</p><p>Polysorbate 80 (50 &mu;g)</p><p>Sodium borate (35 &mu;g)</p><p>Water for injections (QS)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                1 dose of Gardasil suspension for injection contains 0.5 ml.

Prior to agitation, Gardasil may appear as a clear liquid with a white precipitate. After thorough agitation, it is a white, cloudy liquid.

Gardasil is available in packs of 1, 10 or 20 pre-filled syringes. Not all pack sizes are marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder:</strong></p><p>Merck Sharp &amp; Dohme B.V.,</p><p>Waarderweg 39 ,2031 BN Haarlem,</p><p>P.O.Box 581, 2003 Haarlem, the Netherlands</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Merck, Sharp &amp; Dohme LLC<br />770 Sumneytown Pike, West Point, PA 19486, US.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 Oct 2024

To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance Centre (NPC):
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa

•	Other GCC States: 
Please contact the relevant competent authority.

This is a Medicament
-	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to Instructions are dangerous for you.
7.	Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
8.	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
9.	Do not by yourself interrupt the period of treatment prescribed for you.
10.	Do not repeat the same prescription without consulting your doctor.
11.	Keep all medicaments out of reach of children.
Council of Arab Health Ministers  
 Union of Arab Pharmacists

This patient information leaflet is approved by the Saudi Food & Drug Authority. 



The following information is intended for medical or healthcare professionals only:

-	Gardasil is available in a pre-filled syringe ready to use for intramuscular injection (IM), preferably in the deltoid area of the upper arm.
-	If 2 needles of different lengths are provided in the pack, choose the appropriate needle to ensure an IM administration depending on your patient’s size and weight.
-	Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration. Discard the product if particulates are present or if it appears discoloured. Any unused product or waste material should be disposed of in accordance with local requirements.

Shake well before use. Attach the needle by twisting in a clockwise direction until the 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>غارداسيل هو لُقاح. يهدف التطعيم باستخدام لُقاح غارداسيل إلى الوقاية من الأمراض الناجمة عن فيروس الورم الحليمي البشري (إش بي في HPV) أنواع 6 و 11 و 16 و 18.</p><p>وتشمل هذه الأمراض الآفات المحتملة التسرطن التي تصيب الأعضاء التناسلية عند الإناث (عنق الرحم، الفرج، والمهبل)؛ الآفات المحتملة التسرطن التي تصيب الشرج؛ والثآليل التناسلية عند الذكور والإناث؛ وسرطان عنق الرحم والشرج. أنواع فيروس الورم الحليمي البشري 16 و 18 هي المسؤولة عن حوالي 70٪ من حالات سرطان عنق الرحم؛ 75-80٪ من حالات سرطان الشرج؛ 70٪ من الآفات المحتملة التسرطن التي تصيب الفرج والمهبل المرتبطة بفيروس الورم الحليمي البشري؛ 75٪ من الآفات المحتملة التسرطن التي تُصيب الشرج والمرتبطة بفيروس الورم الحليمي البشري. أنواع فيروس الورم الحليمي البشري 6 و 11 هي المسؤولة عن ما يقرب من 90٪ من حالات ثآليل الأعضاء التناسلية.</p><p>ويهدف التطعيم باستخدام لقاح غارداسيل إلى منع حدوث هذه الأمراض. لا يُستخدم اللّقاح في علاج الأمراض المرتبطة بفيروس الورم الحليمي البشري. غارداسيل ليس له أي تأثير في الأفراد المصابين بعدوى مستديمة أو بمرض مرتبط بأي نوع من أنواع فيروس الورم الحليمي البشري الموجودة في اللقاح. ومع ذلك، يمكن أن يُعطى غارداسيل للأفراد االمصابين بعدوى بنوع أو أكثر من أنواع فيروس الورم الحليمي البشري الموجودة في اللقاح، لأنه يمكن أن يوفر حماية من الإصابة بالعدوى المرتبطة بالأنواع الأخرى من فيروس الورم الحليمي البشري الموجودة في اللقاح.</p><p>لا يمكن أن يسبب غارداسيل الأمراض التي يحمي منها.</p><p>يُحفّز غارداسيل الجسم على انتاج أجسام مضادة خاصة بكل نوع وقد أثبتت التجارب السريرية قدرته على منع حدوث &nbsp;الأمراض المرتبطة بفيروس الورم الحليمي البشري للأنواع&nbsp; 6، 11، 16، و 18 لدى النساء اللاتي تتراوح أعمارهن بين 16-45 سنة من العمر ولدى الرجال الذين تتراوح أعمارهم من 16-26 سنة من العمر. كما يُحفّز اللقاح الجسم أيضا على إنتاج أجسام مضادة خاصة بكل نوع لدى الأطفال والمراهقين الذين تتراوح أعمارهم بين 9 و 15 عاما.</p><p>يجب استخدام غارداسيل وفقا للإرشادات الرسمية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتلقى غارداسيل إذا:</strong><br />&bull;&nbsp;&nbsp;&nbsp; كان لديك أو لدى طفلك حساسية&nbsp; (فرط الحساسية) نحو أي من المواد الفعالة أو أي من مكونات<br />&nbsp;&nbsp;&nbsp;&nbsp; غارداسيل الأخرى (المدرجة ضمن فقرة &quot;مكونات أخرى&quot; - انظر الفقرة رقم 6).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; تعرّضت أنت أو طفلك إلى رد فعل تحسسي بعد تلقي جرعة من غارداسيل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; كنت مصاب أنت أو طفلك بمرض مصحوب بارتفاع شديد في درجة الحرارة. ومع ذلك، فإن وجود<br />&nbsp;&nbsp;&nbsp;&nbsp; حمى &nbsp;خفيفة أو عدوى الجهاز التنفسي العلوي (على سبيل المثال الزّكام) في حد ذاتها ليس سببا لتأخير<br />&nbsp;&nbsp;&nbsp;&nbsp; التطعيم.</p><p dir="RTL"><strong>المحاذير والاحتياطات</strong><br />أخبر طبيبك أو الصيدلي أو الممرض قبل التطعيم إذا كنت تعاني أنت أو طفلك من:<br />&bull; &nbsp;&nbsp;&nbsp;اضطراب نزفي (وهو مرض يجعلك تنزف أكثر من المعتاد)، على سبيل المثال الهيموفيليا</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;ضعف في جهاز المناعة، على سبيل المثال بسبب عيب وراثي، عدوى فيروس نقص المناعة البشري<br />&nbsp;&nbsp;&nbsp; &nbsp;أو بسبب تناول الأدوية التي تؤثر على الجهاز المناعي.</p><p dir="RTL">يمكن أن يحدث إغماء، يرافقه أحيانا السقوط (غالبًا لدى المراهقين) بعد تلقي أي حقنة. لذلك أخبر الطبيب أو الممرض إذا تعرّضت في السابق للإغماء عند تلقيك لحقنة.</p><p dir="RTL">كما هو الحال مع أي لقاح، قد لا يؤمّن غارداسيل حماية كاملة 100٪ للأفراد الذين يتلقّون اللقاح.</p><p dir="RTL">غارداسيل لا يحمي ضد كل نوع من أنواع فيروس الورم الحليمي البشري. ولذلك ينبغي الاستمرار في استخدام الاحتياطات المناسبة ضد الأمراض المنقولة عن طريق الاتصال الجنسي.</p><p dir="RTL">غارداسيل لا يحمي ضد الأمراض الأخرى التي لا يسببها فيروس الورم الحليمي البشري.</p><p dir="RTL">التطعيم لا يُعدّ بديلا عن فحص عنق الرحم الروتيني. يجب أن تستمري في متابعة ارشادات طبيبك حول مسحة عنق الرحم / فحص بابانيكولاو &quot;Pap&quot; والالتزام بتدابير الوقاية والحماية.</p><p dir="RTL"><em>ما هي المعلومات الهامة الأخرى التي يجب أن تعرفها أنت أو طفلك حول غارداسيل</em></p><p dir="RTL">وأجريت دراسات متابعة طويلة الأجل لتحديد مدة الحماية. لم يتم تحديد الحاجة إلى جرعة معززة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أو لقاحات أخرى مع غارداسيل</strong><br />يمكن إعطاء غارداسيل في نفس الوقت مع لقاح التهاب الكبد ب أو مع اللقاح المُنشّط المشترك الذي يحتوي على الدفتيريا (d) والكزاز (T) مع إما الشاهوق &quot;السعال الديكي&quot; [اللاخلوي، المكوّن] (ap) و / أو شلل الأطفال [المُضعّف] (IPV) (لقاحات الدفتيريا، والكزاز، والشاهوق اللاخلوي &quot;dTap&quot;، أو الدفتيريا، والكزاز، وشلل الأطفال المُضعّف &quot;dT-IPV&quot;، أو الدفتيريا، والكزاز، والشاهوق اللاخلوي، وشلل الأطفال المُضعّف &quot;dTap-IPV &quot;) في مواضع حقن منفصلة (جزء آخر من جسمك، على سبيل المثال الذراع أو الساق الأخرى) خلال نفس الزيارة للعيادة.</p><p dir="RTL">قد لا يؤدي التطعيم بغارداسيل إلى التأثير الأمثل إذا:<br />&bull; تم إعطاؤه بالتزامن مع الأدوية التي تُثبط جهاز المناعة.</p><p dir="RTL">لم تُثبت التجارب السريرية أنّ استخدام وسائل منع الحمل عن طريق الفم أو غيرها (مثل حبوب منع الحمل) يقلل من الحماية المُكتسبة من خلال جارداسيل.</p><p dir="RTL">یرجی إخبار الطبیب أو الصیدلي إذا کنت أنت أو طفلك تتناول أو تناولت مؤخرا أدویة أخرى، بما في ذلك الأدویة التي یتم الحصول علیھا بدون وصفة طبیة.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong><strong> </strong><strong>و الخصوبه</strong></p><p dir="RTL">استشيري طبيبك قبل تناول هذا الدواء إذا كنت حاملًا أو مرضعة، تعتقدين أنك قد تكونين حاملًا أو تخططين للحمل. &nbsp;&nbsp;<br />يمكن إعطاء غارداسيل للنساء المُرضعات &nbsp;أو اللاتي يعتزمن ممارسة الرضاعة الطبيعية.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لم تُجرى أي دراسات حول تأثيرات هذا اللقاح على القدرة على القيادة واستخدام الآلات.</p><p dir="RTL"><strong>غارداسيل</strong><strong> </strong><strong>يحتوي</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الصوديوم</strong></p><p dir="RTL">&nbsp;يحتوي هذا الدواء على أقل من 1 مليمول صوديوم 23 &nbsp;ملغ لكل جرعة ، أي &quot;خالي من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يتم إعطاء غارداسيل على شكل حقنة من قبل الطبيب. غارداسيل مُعدّ للاستخدام لدى المراهقين والبالغين بدءًا من عمر 9 سنوات وما فوق.</p><p><strong><u>إذا كنت ضمن الفئة العمرية 9 إلى 13 سنة </u></strong></p><p>يمكن إعطاء غارداسيل وفقا لجدول مكوّن من جرعتين:</p><p>- الحقنة الأولى: في أي تاريخ تختاره<br />- الحقنة الثانية: تُعطى بعد مرور 6 أشهر من تاريخ الحقنة الأولى</p><p>إذا تم إعطاء جرعة اللقاح الثانية في وقت أقل من 6 أشهر بعد الجرعة الأولى، ينبغي دائما إعطاء جرعة ثالثة.</p><p>أو كبديل عن ذلك، يمكن إعطاء غارداسيل وفقا لجدول مكون من 3 جرعات:<br />- الحقنة الأولى: في أي تاريخ تختاره.<br />- الحقنة الثانية: بعد مرور شهرين من تاريخ الحقنة الأولى<br />- الحقنة الثالثة: بعد مرور 6 شهور من تاريخ الحقنة الأولى</p><p>وينبغي إعطاء الجرعة الثانية بعد مرور شهر واحد على الأقل من تاريخ الجرعة الأولى، وينبغي إعطاء الجرعة الثالثة بعد مرور3 أشهر على الأقل من تاريخ الجرعة الثانية. وينبغي إعطاء الجرعات الثلاث جميعها خلال فترة سنة واحدة. يرجى التحدث إلى طبيبك للحصول على مزيد من المعلومات.</p><p><strong><u>إذا كنت تبلغ 14 سنة من العمر وما فوق</u></strong><br />يجب إعطاء غارداسيل وفقا لجدول مكون من 3 جرعات:<br />- الحقنة الأولى: في أي تاريخ تختاره.<br />- الحقنة الثانية: بعد مرور شهرين من تاريخ الحقنة الأولى<br />- الحقنة الثالثة: بعد مرور 6 شهور من تاريخ الحقنة الأولى</p><p>وينبغي إعطاء الجرعة الثانية بعد مرور شهر واحد على الأقل من تاريخ الجرعة الأولى، وينبغي إعطاء الجرعة الثالثة بعد مرور3 أشهر على الأقل من تاريخ الجرعة الثانية. وينبغي إعطاء الجرعات الثلاث جميعها خلال فترة سنة واحدة. يرجى التحدث إلى طبيبك للحصول على مزيد من المعلومات.</p><p>من المستحسن أن يُكمل الأفراد الذين يتلقون الجرعة الأولى من غارداسيل دورة التطعيم بأكملها.</p><p>يُعطى غارداسيل على شكل حقنة من خلال الجلد في العضل (وتُفضل العضلات في الجزء العلوي من الذراع أو الفخذ).</p><p>يجب عدم خلط اللقاح في نفس المحاقن مع أي لقاحات ومحاليل أخرى.</p><p><strong>إذا نسيت أن تتلقى إحدى جرعات غارداسيل</strong><br />إذا نسيت أن تتلقى إحدى جرعات غارداسيل المُجدولة، سوف يقرر الطبيب متى يمكن إعطاؤك الجرعة الفائتة.</p><p>من المهم أن تتبع تعليمات الطبيب أو الممرض فيما يتعلق بزيارات المتابعة لتلقي الجرعات المُجدولة. إذا نسيت أو لم تكن قادرا على العودة إلى الطبيب في الوقت المحدد، استشر الطبيب. عندما تتلقى الجرعة الأولى من غارداسيل، ينبغي أن تُكمل دورة التطعيم مع غارداسيل نفسه، وليس مع أي لقاح من لقاحات فيروس الورم الحليمي البشري الأخرى.</p><p>إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع سائر اللقاحات، يمكن أن يُسبب غارداسيل آثارًا جانبيّة لكنها لا تحدث لدى جميع من يتلقاه.</p><p dir="RTL">قد تظهر الآثار الجانبيّة التالية بعد تلقّي لقاح غارداسيل:<br />شائعة جدًا (تحدث لدى أكثر من شخص من بين 10 أشخاص) تشمل الآثار الجانبية التي تحدث في موضع&nbsp; الحقن وهي: ألم، وتورم واحمرار. كما لوحظ حدوث صداع.</p><p dir="RTL">شائعة (تحدث لدى أكثر من شخص من بين 100 أشخاص)، تشمل الآثار الجانبية التي تحدث في موضع الحقن وهي: كدمات، حكة، ألم في الأطراف. كما تم الإبلاغ عن حدوث الحمى والغثيان.</p><p dir="RTL">غير شائعة (تحدث إلى ما يصل إلى شخص من بين 100 أشخاص) : كتلة في موقع الحقن.</p><p dir="RTL">نادرة (تحدث لدى أقل من شخص من بين 1000 أشخاص): الشرى (أرتيكاريا)</p><p dir="RTL">نادرة جدًا (تحدث لدى أقل من شخص من 10000 أشخاص)، تم الإبلاغ عن حدوث صعوبة في التنفس (تشنج في القصبات الهوائية).</p><p dir="RTL">وقد ظهر المزيد من الصداع والتورّم في موقع الحقن عند إعطاء غارداسيل مع لقاح الجرعة المُنشطة من الخناق، والكزاز، الشاهوق [اللاخلوي، المكوّن] وشلل الأطفال [المُضعّف] خلال نفس الزيارة &nbsp;للعيادة.</p><p dir="RTL"><em>الأثار الجانبيّة التي أُبلغ عنها خلال مرحلة ما بعد التسويق تتضمن:</em><br />تم الإبلاغ عن حدوث الإغماء، المصحوب أحيانا بالارتعاش أو التيبّس. وعلى الرغم من أن حدوث نوبات الإغماء غير شائع، إلا أنه ينبغي مراقبة المرضى لمدة 15 دقيقة بعد تلقي لقاح فيروس الورم الحليمي البشري.</p><p dir="RTL">وتم الإبلاغ عن حدوث تفاعلات تحسسية التي قد تشمل صعوبة في التنفس، والصفير أثناء التنفس&nbsp; (تشنج القصبات الهوائية)، والشرى والطفح الجلدي. وكانت بعض ردود الفعل هذه شديدة.</p><p dir="RTL">كما هو الحال مع اللقاحات الأخرى، الآثار الجانبية التي تم الإبلاغ عنها أثناء الاستخدام العام تشمل: تورم الغدد (الرقبة، الإبط، أو الفخذ). ضعف العضلات، أحاسيس غير طبيعية، وخز في الذراعين والساقين والجزء العلوي من الجسم، أو الارتباك (متلازمة غيلان باريه، التهاب الدماغ و النخاع الحاد المُنتثر). والدوخة، والتقيؤ، وآلام المفاصل، والعضلات المؤلمة، والتعب غير المعتاد أو ضعف، قشعريرة، والشعور عموما بالتوعك، والنزيف أو ظهور كدمات بسهولة أكبر من المعتاد، والعدوى الجلدية في موضع الحقن.</p><p dir="RTL"><strong>الإبلاغ عن </strong>الأعراض <strong>الجانبية</strong><br />إذا تعرّضت لأي آثار جانبية، تحدث مع طبيبك أو الصيدلي أو الممرض. ويشمل ذلك أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. یمکنك أیضا الإبلاغ عن الأعراض الجانبیة مباشرة من خلال&quot; المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء&quot;. یمکنك المساعدة في توفیر المزید من المعلومات حول سلامة ھذا الدواء من خلال الإبلاغ عن الأعراض الجانبیة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ هذا اللقاح بعيدا عن مرأى ومتناول الأطفال.<br />لا تستخدم هذا اللقاح بعد تاريخ انتهاء الصالحية المدوّن على ملصق الحُقنة و العبوة الخارجية (بعدEXP).<br />يُحفظ في الثلاجة (2 درجة مئوية - 8 درجة مئوية).<br />لا يُجمد.<br />تُحفظ الحُقنة في العبوة الخارجية من أجل حمايتها من الضوء.<br />لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المواد الفعالة هي: البروتين المنقى للغاية الغير مُعدٍ لكل نوع من أنواع فيروس الورم الحليمي البشري التالية (6 و 11 و 16 و 18).<br />تحتوي الجرعة الواحدة (0.5 مل) على ما يقرب من:</p><p>فيروس الورم الحليمي البشري<sup>1</sup> نوع 6 بروتين L1<sup>3،2 </sup>&nbsp;&nbsp;&nbsp;&nbsp;20 ميكروجرام<br />فيروس الورم الحليمي البشري<sup>1</sup> نوع 11 بروتين L1<sup>3،2</sup>&nbsp;&nbsp; 40 ميكروجرام<br />فيروس الورم الحليمي البشري<sup>1</sup> نوع 16 بروتين L1<sup>3،2</sup>&nbsp;&nbsp; 40 ميكروجرام<br />فيروس الورم الحليمي البشري<sup>1</sup> نوع 18 بروتين L1<sup>3،2</sup>&nbsp;&nbsp; 20 ميكروجرام</p><p><sup>1</sup> فيروس الورم الحليمي البشري = إش بي في HPV<br /><sup>2</sup> بروتين L1 على هيئة جزيئات تشبه الفيروس أُنتجت في خلايا فطر الخميرة (سكروميسز سيريفيسياي CANADE&nbsp;3سي-5 (سلالة 1895)) باستخدام تقنية الهندسة الوراثية للحمض النووي.<br /><sup>3</sup> مُمتَزّ على كبريتات هيدروكسي فوسفات الألمنيوم الغير متبلور المُساعد (0.225 مجم ألمنيوم Al)</p><p>المكونات الأخرى في مُعلّق اللقاح هي:<br />كلوريد الصوديوم ( 56&sbquo;9 ملغم)</p><p>إل- هيستيدين&nbsp; ( 78&sbquo;0 ملغم)</p><p>بوليسوربات 80&nbsp; (50 ميكروجرام)</p><p>بورات الصوديوم (35 ميكروجرام)</p><p>الماء المُخصّص للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>تتكون الجرعة الواحدة لمُعلّق لقاح غارداسيل المُخصّص للحقن من 0.5 ملل. قد يبدو غارداسيل كسائل صافٍ مع راسب أبيض قبل رجّ القارورة. ولكنه يتحول إلى سائل مُعكّر أبيض بعد الرجّ الجيد. يتوفّر غارداسيل في عُلب تحتوي على 1، 10 أو 20 حُقن مُسبقة التعبئة. قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>حامل رخصة التسويق</strong></p><p>ميرك شارب و دوهم بي. في.،</p><p>واردرويج ٣٩، ٢٠٣١&nbsp;بي ان هارلم</p><p>صندوق بريد&nbsp; ٥٨١، ٢٠٠٣ بي سي هارلم</p><p>هولندا</p><p><strong>الشركة المُصنّعة</strong></p><p>شركة ميرك شارب ودوهم ذ م م،</p><p>770 سومنييتاون بايك، ويست بوينت، بنسلفانيا 19486، الولايات المتحدة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تمت أخر مُراجعة لهذه النشرة بتاريخ اكتوبر 2024
للإبلاغ عن الأعراض الجانبية:
•	المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية
للاتصال باالهيئة العامة للغذاء والدواء: 1999
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: https://ade.sfda.gov.sa

•	دول الخليج الأخرى
الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.

(ان هذا الدواء)
- الدواء مستحضر يؤثر على صحتك و استهلاكه خلافا للتعليمات يعرضك للخطر
- اتبع بدقة وصفة الطبيب و طريقة الاستعمال المنصوص عليها و تعليمات الصيدلاني الذي صرفها لك
- إن الطبيب و الصيدلي هما الخبيران بالدواء و بنفعه و ضرره
- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الادوية في متناول ايدي الاطفال

مجلس وزراء الصحة العرب
و اتحاد الصيادلة العرب
تمت الموافقة على نشرة المعلومات هذه للمريض من قبل الهيئة العامة للغذاء والدواء السعودية
¬¬¬
المعلومات التالية مُوجهة  فقط لأخصائي الرعاية الطبية و الصحية:
-	يتوفر جارداسيل في حُقن معبئة مسبقاً جاهزة للاستخدام للحقن العضلي، يفضل أن تكون في منطقة الدالية للقسم العلوي من الذراع.
-	إذا نوفرت الإبر عدد 2 ذات أطوال مختلفة في العبوة، اختيار الإبرة المناسبة لضمان الحقن العضلي المناسب تبعاً لحجم ووزن المريض.
-	ينبغي تفتيش الأدوية التي تُعطى عن طريق الحقن بصريا للتحقق من وجود للجسيمات وتغير لونها قبل إعطائها. يجب عدم إستخدام المنتج إذا كانت الجسيمات موجودة أو إذا تغير لونها. ينبغي التخلص من أي منتج غير مستخدم أو النفايات وفقا للمتطلبات المحلية.  

رُج جيدا قبل الاستخدام. قُم بوضع الإبرة عن طريق  الإلتواء في اتجاه عقارب الساعة حتى يتم تثبيت الإبرة بشكل أمن في الحقنة. يجب أعطاء الجرعة كاملة وفقا للبروتوكول القياسي.

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                GardasilTM, suspension for injection in a pre-filled syringe.
Quadrivalent Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant).

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 dose (0.5 ml) contains approximately:

Human Papillomavirus1 Type 6 L1 protein2,3              20 micrograms Human Papillomavirus1 Type 11 L1 protein2,3           40 micrograms Human Papillomavirus1 Type 16 L1 protein2,3          40 micrograms Human Papillomavirus1 Type 18 L1 protein2,3          20 micrograms.

1Human Papillomavirus = HPV.
2L1 protein in the form of virus-like particles produced in yeast cells (Saccharomyces cerevisiae
CANADE 3C-5 (Strain 1895)) by recombinant DNA technology.
3adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.225 milligrams Al).

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gardasil, suspension for injection in a pre-filled syringe.

	
Prior to agitation, Gardasil may appear as a clear liquid with a white precipitate. After thorough agitation, it is a white, cloudy liquid.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gardasil is a vaccine for use from the age of 9 years for the prevention of:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers&nbsp; and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV)</p><p>types</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;genital warts (condyloma acuminata) causally related to specific HPV types.</p><p>&nbsp;</p><p>See sections 4.4 and 5.1 for important information on the data that support this indication. The use of Gardasil should be in accordance with official recommendations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p><em>Individuals 9 to and including 13 years of age</em></p><p>Gardasil can be administered according to a 2-dose schedule (0.5 ml at 0, 6 months) (see section 5.1).</p><p>&nbsp;</p><p>If the second vaccine dose is administered earlier than 6 months after the first dose, a third dose should</p><p>always be administered.</p><p>&nbsp;</p><p>Alternatively, Gardasil can be administered according to a 3-dose (0.5 ml at 0, 2, 6 months) schedule. The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose. All three doses should be given within a 1-year period.</p><p>&nbsp;</p><p><em>Individuals 14 years of age and older</em></p><p>Gardasil should be administered according to a 3-dose (0.5 ml at 0, 2, 6 months) schedule.</p><p>&nbsp;</p><p>The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose. All three doses should be given within a 1-year period.</p><p>&nbsp;</p><p>The use of Gardasil should be in accordance with official recommendations.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Gardasil in children below 9 years of age have not been established. No data are available (see section 5.1).</p><p>&nbsp;</p><p>It is recommended that individuals who receive a first dose of Gardasil complete the vaccination course with Gardasil (see section 4.4).</p><p>&nbsp;</p><p>The need for a booster dose has not been established<em>.</em></p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>The vaccine should be administered by intramuscular injection. The preferred site is the deltoid area of the upper arm or in the higher anterolateral area of the thigh.</p><p>&nbsp;</p><p>Gardasil must not be injected intravascularly. Neither subcutaneous nor intradermal administration has been studied. These methods of administration are not recommended (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients.

Individuals who develop symptoms indicative of hypersensitivity after receiving a dose of Gardasil should not receive further doses of Gardasil.

Administration of Gardasil should be postponed in individuals suffering from an acute severe febrile illness. However, the presence of a minor infection, such as a mild upper respiratory tract infection or low-grade fever, is not a contraindication for immunisation.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p>The decision to vaccinate an individual should take into account the risk for previous HPV exposure and potential benefit from vaccination.</p><p>&nbsp;</p><p>As with all injectable vaccines, appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the vaccine.</p><p>&nbsp;</p><p>Syncope (fainting), sometimes associated with falling, can occur following, or even before, any vaccination, especially in adolescents as a psychogenic response to the needle injection. This can be</p><p>&nbsp;</p><p>accompanied by several neurological signs such as transient visual disturbance, paraesthesia, and tonic-clonic limb movements during recovery. Therefore, vaccinees should be observed for approximately 15 minutes after vaccine administration. It is important that procedures are in place to avoid injury from faints.</p><p>&nbsp;</p><p>As with any vaccine, vaccination with Gardasil may not result in protection in all vaccine recipients.</p><p>&nbsp;</p><p>Gardasil will only protect against diseases that are caused by HPV types 6, 11, 16 and 18 and to a limited extent against diseases caused by certain related HPV types (See section 5.1). Therefore, appropriate precautions against sexually transmitted diseases should continue to be used.</p><p>&nbsp;</p><p>Gardasil is for prophylactic use only and has no effect on active HPV infections or established clinical disease. Gardasil has not been shown to have a therapeutic effect. The vaccine is therefore, not indicated for treatment of cervical cancer, high-grade cervical, vulvar, and vaginal dysplastic lesions or genital warts. It is also not intended to prevent progression of other established HPV-related lesions.</p><p>&nbsp;</p><p>Gardasil does not prevent lesions due to a vaccine HPV type in individuals infected with that HPV type at the time of vaccination (see section 5.1).</p><p>&nbsp;</p><p>The use of Gardasil in adult women should take into consideration the variability of HPV type prevalence in different geographical areas.</p><p>&nbsp;</p><p>Vaccination is not a substitute for routine cervical screening. Since no vaccine is 100 % effective and Gardasil will not provide protection against every HPV type, or against existing HPV infections, routine cervical screening remains critically important and should follow local recommendations.</p><p>&nbsp;</p><p>Safety and immunogenicity of the vaccine have been assessed in individuals aged from 7 to 12 years who are known to be infected with human immunodeficiency virus (HIV) (see section 5.1).</p><p>Individuals with impaired immune responsiveness, due to either the use of potent immunosuppressive therapy, a genetic defect, or other causes, may not respond to the vaccine.</p><p>&nbsp;</p><p>This vaccine should be given with caution to individuals with thrombocytopaenia or any coagulation disorder because bleeding may occur following an intramuscular administration in these individuals.</p><p>&nbsp;</p><p>Long-term follow-up studies were conducted to determine the duration of protection. (see section 5.1).</p><p>&nbsp;</p><p>There are no safety, immunogenicity or efficacy data to support change during vaccination with Gardasil to other HPV vaccines which do not cover the same HPV types. Therefore, it is important that the same vaccine should be prescribed for the whole dose regimen.</p><p>&nbsp;</p><p><u>Sodium</u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In all clinical trials, individuals who had received immunoglobulin or blood-derived products during the 6 months prior to the first vaccine dose were excluded.</p><p>&nbsp;</p><p><u>Use with other vaccines</u></p><p>&nbsp;</p><p>Administration of Gardasil at the same time (but, for injected vaccines, at a different injection site) as hepatitis B (recombinant) vaccine did not interfere with the immune response to the HPV types. The seroprotection rates (proportion of individuals reaching seroprotective level anti-HBs <u>&gt;</u>10 mIU/ml) were unaffected (96.5% for concomitant vaccination and 97.5% for hepatitis B vaccine only). Anti- HBs geometric mean antibody titres were lower on co-administration, but the clinical significance of this observation is not known.</p><p>&nbsp;</p><p>Gardasil may be administered concomitantly with a combined booster vaccine containing diphtheria (d) and tetanus (T) with either pertussis [acellular, component] (ap) and/or poliomyelitis [inactivated] (IPV) (dTap, dT-IPV, dTap-IPV vaccines) with no significant interference with antibody response to any of the components of either vaccine. However, a trend of lower anti-HPV GMTs was observed in the concomitant group. The clinical significance of this observation is not known.&nbsp; This is based on the results from a clinical trial in which a combined dTap-IPV vaccine was administered concomitantly</p><p>with the first dose of Gardasil. (see section 4.8).</p><p>&nbsp;</p><p>The concomitant administration of Gardasil with vaccines other than the ones above has not been studied.</p><p>&nbsp;</p><p><u>Use with hormonal contraceptives</u></p><p>&nbsp;</p><p>In clinical studies, 57.5% of women aged 16 to 26 years and 31.2% of women aged 24 to 45 years who received Gardasil used hormonal contraceptives during the vaccination period. Use of hormonal contraceptives did not appear to affect the immune response to Gardasil.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>Specific studies of the vaccine in pregnant women were not conducted. During the clinical development program, 3,819 women (vaccine = 1,894 vs. placebo = 1,925) reported at least one pregnancy. There were no significant differences in types of anomalies or proportion of pregnancies with an adverse outcome in Gardasil and placebo treated individuals. These data on pregnant women (more than 1000 exposed outcomes) indicate no malformative nor feto/ neonatal toxicity.</p><p>&nbsp;</p><p>The data on Gardasil administered during pregnancy did not indicate any safety signal. However, these data are insufficient to recommend use of Gardasil during pregnancy. Vaccination should be</p><p>postponed until completion of pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>In breast-feeding mothers given Gardasil or placebo during the vaccination period of the clinical trials the rates of adverse reactions in the mother and the breastfed infant were comparable between the vaccination and the placebo groups. In addition, vaccine immunogenicity was comparable among breastfeeding mothers and women who did not breastfeed during the vaccine administration.</p><p>Therefore Gardasil can be used during breast-feeding. <u>Fertility</u></p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity</p><p>(see section 5.3). No effects on male fertility were observed in rats (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Undesirable effects</p><p><strong>&nbsp;</strong></p><p><strong><em>A.&nbsp;&nbsp; </em></strong><strong><em>Summary of the safety profile</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>In 7 clinical trials (6 placebo-controlled), individuals were administered Gardasil or placebo on the day of enrolment and approximately 2 and 6 months thereafter. Few individuals (0.2 %) discontinued due to adverse reactions. Safety was evaluated in either the entire study population (6 studies) or in a</p><p>&nbsp;</p><p>predefined subset (one study) of the study population using vaccination report card (VRC)-aided surveillance for 14 days after each injection of Gardasil or placebo. The individuals who were monitored using VRC-aided surveillance included 10,088 individuals (6,995 females 9 to 45 years of age and 3,093 males 9 to 26 years of age at enrolment) who received Gardasil and 7,995 individuals (5,692 females and 2,303 males) who received placebo.</p><p>&nbsp;</p><p>The most common adverse reactions observed were injection-site adverse reactions (77.1 % of vaccinees within 5 days following any vaccination visit) and headache (16.6 % of the vaccinees). These adverse reactions usually were mild or moderate in intensity.</p><p>&nbsp;</p><p><strong><em>B.&nbsp;&nbsp; </em></strong><strong><em>Tabulated summary of adverse reactions</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Clinical Trials</p><p>Table 1 presents vaccine-related adverse reactions which were observed among recipients of Gardasil at a frequency of at least 1.0 % and also at a greater frequency than observed among placebo recipients. They are ranked under headings of frequency using the following convention:</p><p>&nbsp;</p><p>[Very Common (&ge;1/10); Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1,000); Very Rare (&lt;1/10,000)]</p><p>&nbsp;</p><p>Post-Marketing Experience</p><p>Table 1 also includes additional adverse events which have been spontaneously reported during the post-marketing use of Gardasil worldwide. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure. Consequently, the frequency of these adverse events is qualified as &quot;not known&quot;.</p><p>&nbsp;</p><p><em>Table&nbsp;1: Adverse Events Following Administration of Gardasil from Clinical Trials and Post-Marketing Surveillance</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Events</strong></p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Injection-site cellulitis *</p></td><td>&nbsp;</td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Not known</p></td><td rowspan="2" style="vertical-align:top"><p>Idiopathic thrombocytopenic purpura*, lymphadenopathy*</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions including anaphylactic/anaphylactoid reactions*</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Acute disseminated encephalomyelitis*, Dizziness<sup>1 </sup>*, Guillain-Barr&eacute; syndrome*, syncope sometimes accompanied by tonic-clonic movements*</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nausea</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vomiting*</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Musculoskeletal and Connective Tissue Disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pain in extremity</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Arthralgia*, Myalgia*</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>At the injection site: erythema, pain, swelling</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pyrexia</p><p>At the injection site: hematoma, pruritus</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Injection site nodule</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Asthenia*, chills*, fatigue*, malaise*</p></td><td>&nbsp;</td></tr><tr><td colspan="3" style="vertical-align:top"><p>* Post&nbsp;Marketing adverse events (frequency cannot be estimated from the available data).</p><p><sup>1 </sup>During clinical trials, dizziness was observed as a common adverse reaction in females. In males, dizziness was not observed at a greater frequency in vaccine recipients than in placebo recipients.</p></td><td>&nbsp;</td></tr></thead></table><p>&nbsp;</p><p>In addition, in clinical trials adverse reactions that were judged to be vaccine- or placebo-related by the study investigator were observed at frequencies lower than 1 %:</p><p>&nbsp;</p><p><u>Respiratory, thoracic and mediastinal disorders:</u></p><p>Very rare: bronchospasm.</p><p>&nbsp;</p><p><u>Skin and subcutaneous tissue disorders:</u></p><p>Rare: urticaria.</p><p>Nine cases (0.06 %) of urticaria were reported in the Gardasil group and 20 cases (0.15 %) were seen in the adjuvant-containing placebo group.</p><p>&nbsp;</p><p>In the clinical studies, individuals in the Safety Population reported any new medical conditions during the follow-up. Among 15,706 individuals who received Gardasil and 13,617 individuals who received placebo, there were 39 cases of non-specific arthritis/arthropathy reported, 24 in the Gardasil group and 15 in the placebo group.</p><p>&nbsp;</p><p>In a clinical trial of 843 healthy adolescent males and females 11-17 years of age, administration of the first dose of Gardasil concomitantly with a combined diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] booster vaccine showed that there was more injection-site swelling and headache reported following concomitant administration. The differences observed were</p><p>&lt; 10 % and in the majority of subjects, the adverse events were reported as mild to moderate in intensity.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been reports of administration of higher than recommended doses of Gardasil.</p><p>&nbsp;</p><p>In general, the adverse event profile reported with overdose was comparable to recommended single doses of Gardasil.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Viral Vaccine, ATC code: J07BM01</p><p>&nbsp;</p><p><em>Mechanism of Action</em></p><p><em>&nbsp;</em></p><p>Gardasil is an adjuvanted non-infectious recombinant quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein of HPV types 6, 11, 16 and 18. The VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. HPV only infects humans, but animal studies with analogous papillomaviruses suggest that the efficacy of LI VLP vaccines is mediated by the development of a humoral immune response.</p><p>&nbsp;</p><p>HPV 16 and HPV 18 are estimated to be responsible for approximately 70 % of cervical cancers and 75-80 % of anal cancers; 80 % of adenocarcinoma in situ (AIS); 45-70 % of high-grade cervical intraepithelial neoplasia (CIN 2/3); 25 % of low grade cervical intraepithelial neoplasia (CIN 1); approximately 70 % of HPV related high-grade vulvar (VIN 2/3) and vaginal (VaIN 2/3) intraepithelial neoplasia and 80 % of HPV related high-grade anal (AIN 2/3) intraepithelial neoplasia. HPV 6 and 11 are responsible for approximately 90 % of genital warts and 10 % of low grade cervical intraepithelial neoplasia (CIN 1). CIN 3 and AIS have been accepted as immediate precursors of invasive cervical cancer.</p><p>The term &quot;premalignant genital lesions&quot; in section 4.1 corresponds to high-grade cervical intraepithelial neoplasia (CIN 2/3), high-grade vulvar intraepithelial neoplasia (VIN 2/3) and high- grade vaginal intraepithelial neoplasia (VaIN 2/3).</p><p>&nbsp;</p><p>The term &quot;premalignant anal lesions&quot; in section 4.1 corresponds to high-grade anal intraepithelial neoplasia (AIN 2/3).</p><p>&nbsp;</p><p>The indication is based on the demonstration of efficacy of Gardasil in females 16 to 45 years of age and in males 16 to 26 years of age and on the demonstration of immunogenicity of Gardasil in 9- to 15-year old children and adolescents.</p><p>&nbsp;</p><p><em>Clinical Studies</em></p><p><em>&nbsp;</em></p><p><u>Efficacy in women 16 through 26 years</u></p><p>&nbsp;</p><p>The efficacy of Gardasil in 16- through 26 year-old women was assessed in 4 placebo-controlled, double-blind, randomised Phase II and III clinical studies including a total of 20,541 women, who were enrolled and vaccinated without pre-screening for the presence of HPV infection.</p><p>&nbsp;</p><p>The primary efficacy endpoints included HPV 6-, 11-, 16-, or 18-related vulvar and vaginal lesions (genital warts, VIN, VaIN) and CIN of any grade and cervical cancers (Protocol 013, FUTURE I), HPV 16- or 18-related CIN 2/3 and AIS and cervical cancers (Protocol 015, FUTURE II), HPV 6-, 11-, 16-, or 18-related persistent infection and disease (Protocol 007), and HPV 16-related persistent</p><p>infection (Protocol 005). The primary analyses of efficacy, with respect to vaccine HPV types (HPV 6, 11, 16, and 18), were conducted in the per-protocol efficacy (PPE) population (i.e. all 3 vaccinations within 1 year of enrollment, no major protocol deviations and na&iuml;ve to the relevant HPV type(s) prior to dose 1 and through 1 month Postdose 3 (Month 7)).</p><p>&nbsp;</p><p>Efficacy results are presented for the combined analysis of study protocols. The efficacy for</p><p>HPV 16/18 related CIN 2/3 or AIS is based on data from protocols 005 (16-related endpoints only), 007, 013, and 015. The efficacy for all other endpoints is based on protocols 007, 013, and 015. The median duration of follow-up for these studies was 4.0, 3.0, 3.0, and 3.0 years for Protocol 005, Protocol 007, Protocol 013, and Protocol 015, respectively. The median duration of follow-up for the combined protocols (005, 007, 013, and 015) was 3.6 years. Results of individual studies support the results from the combined analysis. Gardasil was efficacious against HPV disease caused by each of the four vaccine HPV types. At end of study, individuals enrolled in the two Phase-III studies (Protocol-013 and Protocol-015), were followed for up to 4 years (median 3.7 years).</p><p>&nbsp;</p><p>Cervical Intraepithelial Neoplasia (CIN) Grade 2/3 (moderate to high-grade dysplasia) and adenocarcinoma in situ (AIS) were used in the clinical trials as a surrogate marker for cervical cancer.</p><p>&nbsp;</p><p>In the long-term extension study of Protocol 015, 2,536 women 16-23 years old during vaccination with Gardasil in the base study were followed. In the PPE population no cases of HPV diseases (HPV types 6/11/16/18 related high grade CIN) were observed up to approximately 14 years (median follow- up of 11.9 years). In this study, a durable protection was statistically demonstrated to approximately 12 years.</p><p>&nbsp;</p><p><u>Efficacy in women na&iuml;ve to the relevant vaccine HPV type(s)</u></p><p>&nbsp;</p><p>Efficacy was measured starting after the Month 7 visit. Overall, 73 % of women were na&iuml;ve (PCR negative and seronegative) to all 4 HPV types at enrolment.</p><p>&nbsp;</p><p>The efficacy results for relevant endpoints analysed at 2 years post-enrolment and at end of study (median duration of follow-up = 3.6 years) in the per-protocol population are presented in the Table 2.</p><p>&nbsp;</p><p>In a supplemental analysis, the efficacy of Gardasil was evaluated against HPV 16/18-related CIN 3 and AIS.</p><p><em>Table 2: Analysis of efficacy of Gardasil against high grade cervical lesions in the PPE population</em></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Gardasil</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>%</strong></p><p><strong>Efficacy at 2 years (95</strong><strong> %</strong></p><p><strong>CI)</strong></p></td><td style="vertical-align:top"><p><strong>Gardasil</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>%</strong></p><p><strong>Efficacy*** at end of study</strong></p><p><strong>(95</strong><strong> </strong><strong>% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of</strong></p><p><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>cases&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></u><strong> Number of individuals*</strong></p></td><td style="vertical-align:top"><p><strong>Number of</strong></p><p><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>cases&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></u><strong> Number of individuals*</strong></p></td><td style="vertical-align:top"><p><strong>Number of</strong></p><p><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>cases&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></u><strong> Number of individuals*</strong></p></td><td style="vertical-align:top"><p><strong>Number of</strong></p><p><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>cases&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></u><strong> Number of individuals*</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HPV 16/18-</strong></p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>100.0</p></td><td style="vertical-align:top"><p>2**</p></td><td style="vertical-align:top"><p>112</p></td><td style="vertical-align:top"><p>98.2</p></td></tr><tr><td style="vertical-align:top"><p><strong>related CIN</strong><strong> </strong><strong>2/3 or AIS</strong></p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_3"
   o:spid="_x0000_s2097" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_4" o:spid="_x0000_s2098" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="81" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1048" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>8487</p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_5"
   o:spid="_x0000_s2095" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_6" o:spid="_x0000_s2096" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="81" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1047" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>8460</p></td><td style="vertical-align:top"><p>(92.9,</p><p>100.0)</p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_7"
   o:spid="_x0000_s2093" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_8" o:spid="_x0000_s2094" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="81" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1046" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>8493</p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_9"
   o:spid="_x0000_s2091" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_10" o:spid="_x0000_s2092" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="81" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1045" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>8464</p></td><td style="vertical-align:top"><p>(93.5, 99.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>HPV 16/18-</strong></p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>2**</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>96.9</p></td></tr><tr><td style="vertical-align:top"><p><strong>related CIN 3</strong></p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_11"
   o:spid="_x0000_s2089" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_12" o:spid="_x0000_s2090" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="81" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1044" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>8487</p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_13"
   o:spid="_x0000_s2087" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_14" o:spid="_x0000_s2088" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="81" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1043" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>8460</p></td><td style="vertical-align:top"><p>(86.5,</p><p>100.0)</p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_15"
   o:spid="_x0000_s2085" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_16" o:spid="_x0000_s2086" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="81" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1042" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>8493</p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_17"
   o:spid="_x0000_s2083" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_18" o:spid="_x0000_s2084" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="81" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1041" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>8464</p></td><td style="vertical-align:top"><p>(88.4, 99.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>HPV 16/18-</strong></p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p><strong>related AIS</strong></p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_19"
   o:spid="_x0000_s2081" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_20" o:spid="_x0000_s2082" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="81" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1040" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>8487</p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_21"
   o:spid="_x0000_s2079" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_22" o:spid="_x0000_s2080" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="81" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1039" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>8460</p></td><td style="vertical-align:top"><p>(14.8,</p><p>100.0)</p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_23"
   o:spid="_x0000_s2077" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_24" o:spid="_x0000_s2078" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="81" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1038" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>8493</p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_25"
   o:spid="_x0000_s2075" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_26" o:spid="_x0000_s2076" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="81" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1037" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>8464</p></td><td style="vertical-align:top"><p>(30.6,</p><p>100.0)</p></td></tr></tbody></table><p>*Number of individuals with at least one follow-up visit after Month 7</p><p><strong>**</strong>Based on virologic evidence, the first CIN 3 case in a patient chronically infected with HPV 52 is likely to be causally related to HPV 52. In only 1 of 11 specimens HPV 16 was found (at Month 32.5) and was not detected in tissue excised during LEEP (Loop Electro-Excision Procedure). In the second CIN 3 case observed in a patient infected with HPV 51 at Day 1 (in 2 of 9 specimens); HPV 16 was detected at a Month 51 biopsy (in 1 of 9 specimens) and HPV 56 was detected in 3 of 9 specimens at Month 52 in tissue excised during LEEP.</p><p>***Patients were followed for up to 4 years (median 3.6 years)</p><p>Note: Point estimates and confidence intervals are adjusted for person-time of follow-up.</p><p>&nbsp;</p><p>At end of study and in the combined protocols,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the efficacy of Gardasil against HPV 6-, 11-, 16-, 18-related CIN 1 was 95.9 % (95 % CI: 91.4, 98.4),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the efficacy of Gardasil against HPV 6-, 11-, 16-, 18-related CIN (1, 2, 3) or AIS was 96.0 % (95 % CI: 92.3, 98.2),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the efficacy of Gardasil against HPV 6-, 11-, 16-, 18-related VIN2/3 and VaIN 2/3 was 100 % (95 % CI: 67.2, 100) and 100 % (95 % CI: 55.4, 100), respectively,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the efficacy of Gardasil against HPV 6-, 11-, 16-, 18-related genital warts was 99.0 % (95 % CI: 96.2, 99.9).</p><p>&nbsp;</p><p>In Protocol 012 the efficacy of Gardasil against the 6 month definition of persistent infection [samples positive on two or more consecutive visits 6 months apart (&plusmn;1 month) or longer] related to HPV 16 was 98.7 % (95 % CI: 95.1, 99.8) and 100.0 % (95 % CI: 93.2, 100.0) for HPV 18 respectively, after a follow-up of up to 4 years (mean of 3.6 years). For the 12 month definition of persistent infection, efficacy against HPV 16 was 100.0 % (95 % CI: 93.9, 100.0) and 100.0 % (95 % CI: 79.9, 100.0) for</p><p>HPV 18 respectively<strong>.</strong></p><p><strong>&nbsp;</strong></p><p><u>Efficacy in women with evidence of HPV 6, 11, 16, or 18 infection or disease at day 1</u></p><p>&nbsp;</p><p>There was no evidence of protection from disease caused by vaccine HPV types for which women were PCR positive at day 1. Women who were already infected with one or more vaccine-related HPV types prior to vaccination were protected from clinical disease caused by the remaining vaccine HPV types.</p><p>&nbsp;</p><p><u>Efficacy in women with and without prior infection or disease due to HPV 6, 11, 16, or 18</u></p><p>&nbsp;</p><p>The modified intention to treat (ITT) population included women regardless of baseline HPV status at Day 1, who received at least one vaccination and in whom case counting started at 1 month Postdose</p><p>1. This population approximates to the general population of women with respect to prevalence of HPV infection or disease at enrolment. The results are summarised in Table 3.</p><p>&nbsp;</p><p><em>Table 3: Efficacy of Gardasil in high grade cervical lesions in the modified ITT-population including women regardless of baseline HPV status</em></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Gardasil</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>%</strong></p><p><strong>Efficacy** at 2 years</strong></p><p><strong>(95</strong><strong> </strong><strong>% CI)</strong></p></td><td style="vertical-align:top"><p><strong>Gardasil</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>%</strong></p><p><strong>Efficacy** at end of study</strong></p><p><strong>(95</strong><strong> </strong><strong>% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of</strong></p><p><u>&nbsp; </u><u>&nbsp;&nbsp;&nbsp;&nbsp; </u><strong><u>cases</u></strong><strong><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></strong></p><p><strong>Number of individuals*</strong></p></td><td style="vertical-align:top"><p><strong>Number of</strong></p><p><u>&nbsp; </u><u>&nbsp;&nbsp;&nbsp;&nbsp; </u><strong><u>cases</u></strong><strong><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></strong></p><p><strong>Number of individuals*</strong></p></td><td style="vertical-align:top"><p><strong>Number of</strong></p><p><u>&nbsp; </u><u>&nbsp;&nbsp;&nbsp;&nbsp; </u><strong><u>cases</u></strong><strong><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></strong></p><p><strong>Number of individuals*</strong></p></td><td style="vertical-align:top"><p><strong>Number of</strong></p><p><u>&nbsp; </u><u>&nbsp;&nbsp;&nbsp;&nbsp; </u><strong><u>cases</u></strong><strong><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></strong></p><p><strong>Number of individuals*</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HPV 16- or</strong></p></td><td style="vertical-align:top"><p>122</p></td><td style="vertical-align:top"><p>201</p></td><td style="vertical-align:top"><p>39.0</p></td><td style="vertical-align:top"><p>146</p></td><td style="vertical-align:top"><p>303</p></td><td style="vertical-align:top"><p>51.8</p></td></tr><tr><td style="vertical-align:top"><p><strong>HPV 18-</strong></p><p><strong>related CIN</strong></p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_27"
   o:spid="_x0000_s2073" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_28" o:spid="_x0000_s2074" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="80" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1036" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>9831</p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_29"
   o:spid="_x0000_s2071" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_30" o:spid="_x0000_s2072" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="80" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1035" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>9896</p></td><td style="vertical-align:top"><p>(23.3,</p><p>51.7)</p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_31"
   o:spid="_x0000_s2069" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_32" o:spid="_x0000_s2070" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="81" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1034" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>9836</p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_33"
   o:spid="_x0000_s2067" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAvPRzGMkDAABlCgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWy0Vm1v2zYQ/l5g/4HgxwKOJEe2I6NK
saR1UCBbgzr9ATRFW8IoUiPpl3TYf98dKdmya29Bh+qDRJEPH949d+Tx3ftdLclGGFtpldPkKqZE
KK6LSq1y+vV5NrihxDqmCia1Ejl9EZa+v/3lzTs2XRnWlBUnwKDslOW0dK6ZRpHlpaiZvdKNUDC2
1KZmDn7NKioM2wJzLaNhHI+jmlWK3h6oPjDHyNpUP0AlNf9DFPdMbZgFSsmn/Z7WRsn/PzObqs2D
aebNk0HL+e+bJ0OqIqegnGI1SESjdqCFwW90Mmt1INgtTY14vVySnWd5wbfnEDtHOHROxpP4Bvg5
DCXDSdwO8/LzmUm8/Phv08CUsCQ0emb4Jtpxwbt00rn3YPS6IdfXp27iZM/yCKGwwWlQ56Fz9YIG
ZLH9TRcgG1s77ZPhJyqSDGPIZ5Rx6DW8IIZtghLfBzmF6SHKMyMEpja5TvdKdHjbHGsQ+r0ABwik
zQ+5ftEHSMa1dQ9C+3xim0frfBatCmj56BSt7c+QS8tawpZ9GxHgm5Atfm6CI6s9LOnBYlKSIBqE
eY8YHiHOs1wfYc6xpEeI8yyjHiZJzxoz7kMuewWZfHD+PBNE+QC5zJT1YAd9cGN1krOyiwLfqTYM
0CIMj9fYp3ujLW58jAnk5XOCQQAKQGHMLoBBdwT7TfifYJAXwaNXMYOICJ68Cgw6ITjrg4M5ra9G
cEekP9acf5ucGkoWOV3gHDZtmEOJuibZ4gmHm7T0exT7a70Rz9ojHCqFCevX7bbwASBVHxgU7VDd
WPdtPFnAJH4Pg+XdYPcNoP2Kr8WdrsmltiLEFR32Ad57joL1Nq7VsipmlZTosTWrxb00ZMNQRP+0
Wh/BpM8VpXFaWCb0QAFpxcVS4ivrX1kyTOO7YTaYjW8mg3SWjgYZlJdBnGR32ThOs/TD7G/MzCSd
llVRCPVYKdFV+ST9roTWFTfa6qW74rqOoI5VXHSVHup8Eoc6j6HNRsORT/oj61/pJNQdVfikKQUr
PrZtxyoZ2tGxxV5kcLv7eiFAa9tWbreb+2Pe7e508YJiL+ALp7LRIVXhVuQ+w2spNZjOZdVAVmrz
7bQPcSAKjFCyhTtRTu2fa2YEJfKTsuB0kqaQZs7/pKMJnKLE9EcW/RGmOFDl1FE4JLB57+APpqwb
U61KWCnxCir9KxTMZYVnPHgVbEcvpHVz9yIx3WB74Uuo4okZ9gV8k/7gEWrwdd7mESBg+kGEtRXz
5gts28AbVPKyeWB7T4hOLljtmL8Q4i2u/3/7DwAAAP//AwBQSwMEFAAGAAgAAAAhAJJ9h+AdBwAA
SSAAABoAAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbOxZS28bNxC+F+h/WOy9sWS9YiNyYMly
3MQvREqKHCmJ2mXMXS5Iyo5uRXLqpUCBtOihAXrroSgaoAEa9NIfY8BBm/6IDrkvUqLiB1wgKGwB
xu7sN8PhzOzM7PDO3WcR9Y4xF4TFbb96q+J7OB6xMYmDtv9osP3Zbd8TEsVjRFmM2/4MC//uxqef
3EHrI0qSIUN8PAhxhD0QFIt11PZDKZP1lRUxAjISt1iCY3g2YTxCEm55sDLm6AQWiOjKaqXSXIkQ
if0NkCiVoB6Ff7EUijCivK/EYC9GEax+MJmQEdbY8VFVIcRMdCn3jhFt+yBzzE4G+Jn0PYqEhAdt
v6L//JWNOytoPWOicgmvwbet/zK+jGF8tKrX5MGwWLReb9Sbm4V8DaByEddr9Zq9ZiFPA9BoBDtN
dbFltla79QxrgNJLh+yt1latauEN+bUFnTcb6mfhNSiVX1/Ab293wYoWXoNSfGMB3+isdbZs+RqU
4psL+FZlc6vesuRrUEhJfLSArjSatW6+2wIyYXTHCV9r1Ldbq5nwEgXRUESXWmLCYrks1iL0lPFt
ACggRZLEnpwleIJGEJNdRMmQE2+XBCEEXoJiJoBcWa1sV2rwX/3q+kp7FK1jZHArvUATsUBS+nhi
xEki2/59kOobkLO3b0+fvzl9/vvpixenz3/N1taiLL4dFAcm3/ufvvnn1Zfe37/9+P7lt+nS83hh
4t/98tW7P/78kHjYcWmKs+9ev3vz+uz7r//6+aVD+iZHQxM+IBEW3j4+8R6yCDbo0B8P+eU4BiEi
JsdmHAgUI7WKQ35PhhZ6f4YocuA62LbjYw6pxgW8N31qKdwP+VQSh8QHYWQB9xijHcadVnig1jLM
PJjGgXtxPjVxDxE6dq3dRbHl5d40gRxLXCK7IbbUPKQolijAMZaeesaOMHbs7gkhll33yIgzwSbS
e0K8DiJOkwzI0IqmkmmHROCXmUtB8Ldlm73HXodR16638LGNhHcDUYfyA0wtM95DU4kil8gBiqhp
8F0kQ5eS/RkfmbiekODpAFPm9cZYCBfPAYf9Gk5/AGnG7fY9OotsJJfkyCVzFzFmIrfYUTdEUeLC
9kkcmtjPxRGEKPIOmXTB95j9hqh78AOKl7r7McGWu8/PBo8gw5oqlQGinky5w5f3MLPitz+jE4Rd
qWaTR1aK3eTEGR2daWCF9i7GFJ2gMcbeo88dGnRYYtm8VPp+CFllB7sC6z6yY1Xdx1hgTzc3i3ly
lwgrZPs4YEv02ZvNJZ4ZiiPEl0neB6+bNu9BqYtcAXBAR0cmcJ9Avwfx4jTKgQAZRnAvlXoYIquA
qXvhjtcZt/x3kXcM3sunlhoXeC+BB1+aBxK7yfNB2wwQtRYoA2aAoMtwpVtgsdxfsqjiqtmmTr6J
/dKWboDuyGp6IhKf2wHN9T6N/673gQ7j7IdXjpftevodt2ArWV2y01mWTHbm+ptluPmupsv4mHz8
Tc0WmsaHGOrIYsa66Wluehr/f9/TLHufbzqZZf3GTSfjQ4dx08lkw5Xr6WTK5gX6GjXwSAc9euwT
LZ36TAilfTmjeFfowY+A75nxNhAVn55u4mIKmIRwqcocLGDhAo40j8eZ/ILIsB+iBKZDVV8JCUQm
OhBewgQMjTTZKVvh6TTaY+N02FmtqsFmWlkFkiW90ijoMKiSKbrZKgd4hXitbaAHrbkCivcyShiL
2UrUHEq0cqIykh7rgtEcSuidXYsWaw4tbivxuasWtADVCq/AB7cHn+ltv1EHFmCCeRw052Plp9TV
uXe1M6/T08uMaUUANNh5BJSeXlO6Lt2e2l0aahfwtKWEEW62EtoyusETIXwGZ9GpqBdR47K+Xitd
aqmnTKHXg9Aq1Wjd/pAWV/U18M3nBhqbmYLG3knbb9YaEDIjlLT9CQyN4TJKIHaE+uZCNIDjlpHk
6Qt/lcyScCG3kAhTg+ukk2aDiEjMPUqitq+2X7iBxjqHaN2qq5AQPlrl1iCtfGzKgdNtJ+PJBI+k
6XaDoiyd3kKGT3OF86lmvzpYcbIpuLsfjk+8IZ3yhwhCrNGqKgOOiYCzg2pqzTGBw7AikZXxN1eY
srRrnkbpGErpiCYhyiqKmcxTuE7lhTr6rrCBcZftGQxqmCQrhMNAFVjTqFY1LapGqsPSqns+k7Kc
kTTLmmllFVU13VnMWiEvA3O2vFqRN7TKTQw5zazwaeqeT7lrea6b6xOKKgEGL+znqLoXKAiGauVi
lmpK48U0rHJ2RrVrR77Bc1S7SJEwsn4zFztnt6JGOJcD4pUqP/DNRy2QJnlfqS3tOtjeQ4k3DKpt
Hw6XYTj4DK7geNoH2qqirSoaXMGZM5SL9KC47WcXOQWep5QCU8sptRxTzyn1nNLIKY2c0swpTd/T
J6pwiq8OU30vPzCFGpYdsGa9hX36v/EvAAAA//8DAFBLAwQUAAYACAAAACEAnGZGQbsAAAAkAQAA
KgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc4SPzQrCMBCE74Lv
EPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hFQfCyMLPsN7NN+7IzeWJMk3ccaloBQae8npzhcOsv
uyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIoLnEYcw4nxpIa0cpEfUBXNoOPVuYio2FBqrs0yPZV
dWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5RwTLpRcWoIwGMwdKV2edNS1dgYmGff0m3gAA
AP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAeAgAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRl
bnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCtMD/xwQAAADIBAAALAAAAAAAAAAAAAAAAADYB
AABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQC89HMYyQMAAGUKAAAfAAAAAAAAAAAAAAAAACAC
AABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1sUEsBAi0AFAAGAAgAAAAhAJJ9h+AdBwAA
SSAAABoAAAAAAAAAAAAAAAAAJgYAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAG
AAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAAAAAAAAAAew0AAGNsaXBib2FyZC9kcmF3aW5ncy9f
cmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAABQAFAGcBAAB+DgAAAAA=
">
   <v:shape id="Freeform_x0020_34" o:spid="_x0000_s2068" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="80" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1033" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>9904</p></td><td style="vertical-align:top"><p>(41.1,</p><p>60.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>2/3 or AIS</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>HPV 16/18-</strong></p></td><td style="vertical-align:top"><p>83</p></td><td style="vertical-align:top"><p>127</p></td><td style="vertical-align:top"><p>34.3</p></td><td style="vertical-align:top"><p>103</p></td><td style="vertical-align:top"><p>191</p></td><td style="vertical-align:top"><p>46.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>related CIN</strong><strong> </strong><strong>3</strong></p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_35"
   o:spid="_x0000_s2065" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_36" o:spid="_x0000_s2066" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="80" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1032" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>9831</p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_37"
   o:spid="_x0000_s2063" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_38" o:spid="_x0000_s2064" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="80" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1031" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>9896</p></td><td style="vertical-align:top"><p>(12.7,</p><p>50.8)</p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_39"
   o:spid="_x0000_s2061" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_40" o:spid="_x0000_s2062" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="81" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1030" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>9836</p></td><td style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_41"
   o:spid="_x0000_s2059" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_42" o:spid="_x0000_s2060" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="80" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1029" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>9904</p></td><td style="vertical-align:top"><p>(31.0,</p><p>57.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>HPV 16/18-</strong></p><p><strong>related AIS</strong></p></td><td style="vertical-align:top"><p>5</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_43"
   o:spid="_x0000_s2057" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_44" o:spid="_x0000_s2058" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="80" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1028" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>9831</p></td><td style="vertical-align:top"><p>11</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_45"
   o:spid="_x0000_s2055" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_46" o:spid="_x0000_s2056" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="80" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1027" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>9896</p></td><td style="vertical-align:top"><p>54.3</p><p>(&lt;0, 87.6)</p></td><td style="vertical-align:top"><p>6</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_47"
   o:spid="_x0000_s2053" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_48" o:spid="_x0000_s2054" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="81" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1026" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>9836</p></td><td style="vertical-align:top"><p>15</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_49"
   o:spid="_x0000_s2051" style='width:60.4pt;height:1pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Freeform_x0020_50" o:spid="_x0000_s2052" style='position:absolute;
    width:1208;height:20;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1208,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAnJ53AvwAAANoAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE89a8Mw
EN0L/Q/iCl1KIidDKY6VYBqSdCrUMZ4P62qbWCcjybH676uh0PHxvotDNKO4k/ODZQWbdQaCuLV6
4E5BfT2t3kD4gKxxtEwKfsjDYf/4UGCu7cJfdK9CJ1II+xwV9CFMuZS+7cmgX9uJOHHf1hkMCbpO
aodLCjej3GbZqzQ4cGrocaL3ntpbNRsFTbXUn1Tas4sXH5ujfrlRMyv1/BTLHYhAMfyL/9wfWkHa
mq6kGyD3vwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAAAAAA
AAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAAAAAA
AAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQAnJ53AvwAAANoAAAAPAAAAAAAA
AAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA8wIAAAAA
" path="m1207,l,,,14r1207,l1207,xe" fillcolor="black" stroked="f">
    <v:path arrowok="t" o:connecttype="custom" o:connectlocs="1207,0;0,0;0,14;1207,14;1207,0"
     o:connectangles="0,0,0,0,0"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="80" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1025" type="#_x0000_t75" style='width:60.4pt;height:1pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>9904</p></td><td style="vertical-align:top"><p>60.0</p><p>(&lt;0, 87.3)</p></td></tr></tbody></table><p>*Number of individuals with at least one follow-up visit after 30 days after Day 1</p><p>**Percent efficacy is calculated from the combined protocols. The efficacy for HPV 16/18 related CIN 2/3 or AIS is based on data from protocols 005 (16-related endpoints only), 007, 013, and 015. Patients were followed for up to 4 years (median 3.6 years).</p><p>Note: point estimates and confidence intervals are adjusted for person-time of follow-up.</p><p>&nbsp;</p><p>Efficacy against HPV 6-, 11-, 16-, 18-related VIN 2/3 was 73.3 % (95 % CI: 40.3, 89.4), against</p><p>HPV 6-, 11-, 16-, 18-related VaIN 2/3 was 85.7 % (95 % CI: 37.6, 98.4), and against HPV 6-, 11-, 16-</p><p>, 18-related genital warts was 80.3 % (95 % CI: 73.9, 85.3) in the combined protocols at end of study.</p><p>&nbsp;</p><p>Overall 12 % of the combined study population had an abnormal Pap test suggestive of CIN at Day 1. Among women with an abnormal Pap test at Day 1 who were na&iuml;ve to the relevant vaccine HPV types at Day 1, efficacy of the vaccine remained high. Among women with an abnormal Pap test at Day 1 who were already infected with the relevant vaccine HPV types at Day 1, no vaccine efficacy was observed.</p><p>&nbsp;</p><p><u>Protection Against the Overall Burden of Cervical HPV disease in 16- Through 26-Year-Old Women</u></p><p>&nbsp;</p><p>The impact of Gardasil against the overall risk for cervical, HPV disease (i.e., disease caused by any HPV type) was evaluated starting 30 days after the first dose in 17,599 individuals enrolled in the two Phase III efficacy trials (Protocols 013 and 015). Among women who were na&iuml;ve to 14 common HPV types and had a negative Pap test at Day 1, administration of Gardasil reduced the incidence of</p><p>CIN 2/3 or AIS caused by vaccine- or non-vaccine HPV types by 42.7 % (95 % CI: 23.7, 57.3) and of genital warts by 82.8 % (95 % CI: 74.3, 88.8) at end of study.</p><p>&nbsp;</p><p>In the modified ITT population, the benefit of the vaccine with respect to the overall incidence of CIN 2/3 or AIS (caused by any HPV type) and of genital warts was much lower, with a reduction of</p><p>18.4 % (95 % CI: 7.0, 28.4) and 62.5 % (95 % CI: 54.0, 69.5), respectively, as Gardasil does not impact the course of infections or disease that are present at vaccination onset.</p><p>&nbsp;</p><p><u>Impact on Definitive Cervical Therapy Procedures</u></p><p>&nbsp;</p><p>The impact of Gardasil on rates of Definitive Cervical Therapy Procedures regardless of causal HPV types was evaluated in 18,150 individuals enrolled in Protocol 007, Protocols 013 and 015. In the HPV na&iuml;ve population (na&iuml;ve to 14 common HPV types and had a negative Pap test at Day 1), Gardasil reduced the proportion of women who experienced a definitive cervical therapy procedure (Loop Electro-Excision Procedure or Cold-Knife Conization) by 41.9 % (95 % CI: 27.7, 53.5) at end of study. In the ITT population the corresponding reduction was 23.9 % (95 % CI: 15.2, 31.7).</p><p>&nbsp;</p><p><u>Cross-protective efficacy</u></p><p>&nbsp;</p><p>The efficacy of Gardasil against CIN (any grade) and CIN 2/3 or AIS caused by 10 non-vaccine HPV types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) structurally related to HPV 16 or HPV 18 was evaluated in the combined Phase III efficacy database (N = 17,599) after a median follow-up of</p><p>3.7 years (at end of study). Efficacy against disease endpoints caused by pre-specified combinations of non-vaccine HPV types was measured. The studies were not powered to assess efficacy against disease caused by individual HPV types.</p><p>&nbsp;</p><p>The primary analysis was done in type-specific populations that required women to be negative for the type being analysed, but who could be positive for other HPV types (96 % of the overall population). The primary time point analysis after 3 years did not reach statistical significance for all pre-specified endpoints. The final end-of-study results for the combined incidence of CIN 2/3 or AIS in this population after a median follow-up of 3.7 years are shown in Table 4. For composite endpoints, statistically significant efficacy against disease was demonstrated against HPV types phylogenetically related to HPV 16 (primarily HPV 31) whereas no statistically significant efficacy was observed for HPV types phylogenetically related to HPV 18 (including HPV 45). For the 10 individual HPV types, statistical significance was only reached for HPV 31.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Freeform_x0020_51"
 o:spid="_x0000_s2050" style='position:absolute;left:0;text-align:left;
 margin-left:167.75pt;margin-top:116.2pt;width:2.8pt;height:1pt;z-index:-251658240;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' coordsize="56,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" o:allowincell="f" path="m55,l,,,9r55,l55,xe" fillcolor="black" stroked="f">
 <v:path arrowok="t" o:connecttype="custom" o:connectlocs="34925,0;0,0;0,5715;34925,5715;34925,0"
  o:connectangles="0,0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="3" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png" /><em>Table 4: Results for CIN 2/3 or AIS in Type-Specific HPV-Na&iuml;ve Individuals<sup>&dagger;</sup> (end of study results)</em></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5" style="vertical-align:top"><p>Na&iuml;ve to &ge; 1 HPV Type</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>&nbsp;</em></p><p>Composite Endpoint</p></td><td style="vertical-align:top"><p>Gardasil</p></td><td style="vertical-align:top"><p>Placebo</p></td><td rowspan="2" style="vertical-align:top"><p><em>&nbsp;</em></p><p>% Efficacy</p></td><td rowspan="2" style="vertical-align:top"><p><em>&nbsp;</em></p><p>95 % CI</p></td></tr><tr><td style="vertical-align:top"><p>cases</p></td><td style="vertical-align:top"><p>cases</p></td></tr><tr><td style="vertical-align:top"><p>(HPV 31/45) <sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>43.2 %</p></td><td style="vertical-align:top"><p>12.1, 63.9</p></td></tr><tr><td style="vertical-align:top"><p>(HPV 31/33/45/52/58) <sup>&sect;</sup></p></td><td style="vertical-align:top"><p>111</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>25.8 %</p></td><td style="vertical-align:top"><p>4.6, 42.5</p></td></tr><tr><td style="vertical-align:top"><p>10 non-vaccine HPV</p><p>Types<sup>║</sup></p></td><td style="vertical-align:top"><p>162</p></td><td style="vertical-align:top"><p>211</p></td><td style="vertical-align:top"><p>23.0 %</p></td><td style="vertical-align:top"><p>5.1, 37.7</p></td></tr><tr><td style="vertical-align:top"><p>HPV-16 related types (A9</p><p>species)</p></td><td style="vertical-align:top"><p>111</p></td><td style="vertical-align:top"><p>157</p></td><td style="vertical-align:top"><p>29.1 %</p></td><td style="vertical-align:top"><p>9.1, 44.9</p></td></tr><tr><td style="vertical-align:top"><p>HPV 31</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>55.6 %</p></td><td style="vertical-align:top"><p>26.2, 74.1<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>HPV 33</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>19.1 %</p></td><td style="vertical-align:top"><p>&lt;0, 52.1<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>HPV 35</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>13.0 %</p></td><td style="vertical-align:top"><p>&lt;0, 61.9<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>HPV 52</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>14.7 %</p></td><td style="vertical-align:top"><p>&lt;0, 44.2<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>HPV 58</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>31.5 %</p></td><td style="vertical-align:top"><p>&lt;0, 61.0<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>HPV-18 related types (A7 species)</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>25.9 %</p></td><td style="vertical-align:top"><p>&lt;0, 53.9</p></td></tr><tr><td style="vertical-align:top"><p>HPV 39</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>37.5 %</p></td><td style="vertical-align:top"><p>&lt;0, 69.5<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>HPV 45</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0.0 %</p></td><td style="vertical-align:top"><p>&lt;0, 60.7<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>HPV 59</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>39.9 %</p></td><td style="vertical-align:top"><p>&lt;0, 76.8<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>A5 species (HPV 51)</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>16.3 %</p></td><td style="vertical-align:top"><p>&lt;0, 48.5<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>A6 species (HPV 56)</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>-13.7 %</p></td><td style="vertical-align:top"><p>&lt;0, 32.5<sup>&dagger;</sup></p></td></tr></tbody></table><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The studies were not powered to assess efficacy against disease caused by individual HPV types.</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy was based on reductions in HPV 31-related CIN 2/3 or AIS</p><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy was based on reductions in HPV 31-, 33-, 52-, and 58-related CIN 2/3 or AIS</p><p><sup>║</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes assay-identified non-vaccine HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59.</p><p>&nbsp;</p><p><u>Efficacy in women 24 through 45 years</u></p><p>&nbsp;</p><p>The efficacy of Gardasil in 24- through 45 year-old women was assessed in 1 placebo-controlled, double-blind, randomised Phase III clinical study (Protocol 019, FUTURE III) including a total of 3,817 women, who were enrolled and vaccinated without pre-screening for the presence of HPV infection.</p><p>&nbsp;</p><p>The primary efficacy endpoints included the combined incidence of HPV 6-, 11-, 16- or 18-related and the combined incidence of HPV 16- or HPV 18-related persistent infection (6 month definition), genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers. The median duration of follow-up for this study was 4.0 years.</p><p>&nbsp;</p><p>In the long-term extension study of Protocol 019, 685 women 24-45 years old during vaccination with Gardasil in the base study were followed. In the PPE population, no cases of HPV diseases (HPV types 6/11/16/18 related CIN any grade and Genital Warts) were observed through 10.1 years (median follow-up of 8.7 years).</p><p>&nbsp;</p><p><u>Efficacy in women na&iuml;ve to the relevant vaccine HPV type(s)</u></p><p>&nbsp;</p><p>The primary analyses of efficacy were conducted in the per-protocol efficacy (PPE) population (i.e. all 3 vaccinations within 1 year of enrolment, no major protocol deviations and na&iuml;ve to the relevant HPV type(s) prior to dose 1 and through 1 month Postdose 3 (Month 7)). Efficacy was measured starting after the Month 7 visit. Overall, 67 % of individuals were na&iuml;ve (PCR negative and seronegative) to all 4 HPV types at enrolment.</p><p>&nbsp;</p><p>The efficacy of Gardasil against the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 88.7 % (95 % CI: 78.1, 94.8).</p><p>&nbsp;</p><p>The efficacy of Gardasil against the combined incidence of HPV 16- or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 84.7 %</p><p>(95 % CI: 67.5, 93.7).</p><p>&nbsp;</p><p><u>Efficacy in women with and without prior infection or disease due to HPV 6, 11, 16, or 18</u></p><p>&nbsp;</p><p>The Full Analysis Set population (also known as the ITT population) included women regardless of baseline HPV status at Day 1, who received at least one vaccination and in whom case counting started at Day 1. This population approximates to the general population of women with respect to prevalence of HPV infection or disease at enrolment.</p><p>&nbsp;</p><p>The efficacy of Gardasil against the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 47.2 % (95 % CI: 33.5, 58.2).</p><p>&nbsp;</p><p>The efficacy of Gardasil against the combined incidence of HPV 16- or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 41.6 %</p><p>(95 % CI: 24.3, 55.2).</p><p>&nbsp;</p><p><u>Efficacy in women (16 to 45 years) with evidence of a prior infection with a vaccine HPV type</u> <u>(seropositive) that was no longer detectable at vaccination onset (PCR negative)</u></p><p>&nbsp;</p><p>In post hoc analyses of individuals (who received at least one vaccination) with evidence of a prior infection with a vaccine HPV type (seropositive) no longer detectable (PCR negative) at vaccination onset, the efficacy of Gardasil to prevent conditions due to the recurrence of the same HPV type was 100 % (95 % CI: 62.8, 100.0; 0 vs. 12 cases [n = 2572 from pooled studies in young women]) against HPV 6-, 11-, 16-, and 18-related CIN 2/3, VIN 2/3, VaIN 2/3, and genital warts in women 16 to</p><p>26 years. Efficacy was 68.2 % (95 % CI: 17.9, 89.5; 6 vs. 20 cases [n = 832 from studies in young and adult women combined]) against HPV 16- and 18-related persistent infection in women 16 to 45 years.</p><p>&nbsp;</p><p><u>Efficacy in men 16 through 26 years</u></p><p>&nbsp;</p><p>Efficacy was evaluated against HPV 6-, 11-, 16-, 18-related external genital warts, penile/perineal/perianal intraepithelial neoplasia (PIN) grades 1/2/3, and persistent infection.</p><p>&nbsp;</p><p>The efficacy of Gardasil in 16- through 26 year-old men was assessed in 1 placebo-controlled, double- blind, randomised Phase III clinical study (Protocol 020) including a total of 4,055 men who were enrolled and vaccinated without pre-screening for the presence of HPV infection. The median duration of follow-up was 2.9 years.</p><p>&nbsp;</p><p>In a subset of 598 men (GARDASIL = 299; placebo = 299) in Protocol 020 who self-identified as having sex with men (MSM) efficacy against anal intraepithelial neoplasia (AIN grades 1/2/3) and anal cancer, and intra-anal persistent infection was evaluated.</p><p>&nbsp;</p><p>MSM are at higher risk of anal HPV infection compared to the general population; the absolute benefit of vaccination in terms of prevention of anal cancer in the general population is expected to be very low.</p><p>&nbsp;</p><p>HIV infection was an exclusion criterion (see also section 4.4). <u>Efficacy in Men na&iuml;ve to the relevant vaccine HPV types</u></p><p>The primary analyses of efficacy, with respect to vaccine HPV types (HPV 6, 11, 16, 18), were conducted in the per-protocol efficacy (PPE) population (i.e. all 3 vaccinations within 1 year of enrolment, no major protocol deviations and na&iuml;ve to the relevant HPV type(s) prior to dose 1 and through 1 month Postdose 3 (Month 7)). Efficacy was measured starting after the Month 7 visit. Overall, 83 % of men (87 % of heterosexual subjects and 61 % of MSM subjects) were na&iuml;ve (PCR negative and seronegative) to all 4 HPV types at enrolment.</p><p>&nbsp;</p><p>Anal Intraepithelial Neoplasia (AIN) Grade 2/3 (moderate to high-grade dysplasia) was used in the clinical trials as a surrogate marker for anal cancer.</p><p>&nbsp;</p><p>The efficacy results for relevant endpoints analysed at end of study (median duration of follow-up</p><p>2.4 years) in the per-protocol population are presented in the Table 5. Efficacy against PIN grades 1/2/3 was not demonstrated.</p><p>&nbsp;</p><p><em>Table 5: Efficacy of Gardasil against external genital lesions in the PPE* population of 16-26 year old men</em></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><em>&nbsp;</em></p><p><strong>Endpoint</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Gardasil</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>% Efficacy (95</strong><strong> </strong><strong>%CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>Number of</p><p>cases</p></td><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>Number of</p><p>cases</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>HPV 6/11/16/18-related external genital lesions</p></td></tr><tr><td style="vertical-align:top"><p>External genital lesions</p></td><td style="vertical-align:top"><p>1394</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1404</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>90.6 (70.1. 98.2)</p></td></tr><tr><td style="vertical-align:top"><p>Genital warts</p></td><td style="vertical-align:top"><p>1394</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1404</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>89.3 (65.3, 97.9)</p></td></tr><tr><td style="vertical-align:top"><p>PIN1/2/3</p></td><td style="vertical-align:top"><p>1394</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1404</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>100.0 (-52.1, 100.0)</p></td></tr></tbody></table><p>*The individuals in the PPE population received all 3 vaccinations within 1 year of enrolment, had no major protocol deviations, and were na&iuml;ve to the relevant HPV type(s) prior to dose 1 and through 1 month Postdose 3 (Month 7).</p><p>&nbsp;</p><p>At end of study analysis for anal lesions in the MSM population (median duration of follow-up was</p><p>2.15 years), the preventive effect against HPV 6-, 11-, 16-, 18-related AIN 2/3 was 74.9 % (95 % CI: 8.8, 95.4; 3/194 versus 13/208) and against HPV 16- or 18-related AIN 2/3 86.6 % (95 % CI: 0.0, 99.7; 1/194 versus 8/208).</p><p>&nbsp;</p><p>The duration of protection against anal cancer is currently unknown. In the long-term extension study of Protocol 020, 917 men 16-26 years old during vaccination with Gardasil in the base study were followed. In the PPE population, no cases of HPV types 6/11 related genital warts, HPV 6/11/16/18 external genital lesions or HPV 6/11/16/18 high grade AIN in MSM were observed through 11.5 years (median follow-up of 9.5 years).</p><p>&nbsp;</p><p><u>Efficacy in men with or without prior infection or disease due to HPV 6, 11, 16, or 18</u></p><p>&nbsp;</p><p>The Full Analysis Set population included men regardless of baseline HPV status at Day 1, who received at least one vaccination and in whom case counting started at Day 1. This population approximates to the general population of men with respect to prevalence of HPV infection or disease at enrolment.</p><p>&nbsp;</p><p>The efficacy of GARDASIL against HPV 6-, 11-, 16-, 18-related external genital warts was 68.1 % (95 % CI: 48.8, 79.3).</p><p>&nbsp;</p><p>The efficacy of GARDASIL against HPV 6-, 11-, 16-, 18-related AIN 2/3 and HPV 16- or 18-related AIN 2/3, in the MSM substudy, was 54.2 % (95 % CI: 18.0, 75.3; 18/275 versus 39/276) and 57.5 % (95 % CI: -1.8, 83.9; 8/275 versus 19/276 cases), respectively.</p><p>&nbsp;</p><p><u>Protection Against the Overall Burden of HPV disease in 16- Through 26-Year-Old Men</u></p><p>&nbsp;</p><p>The impact of Gardasil against the overall risk for external genital lesions was evaluated after the first dose in 2,545 individuals enrolled in the Phase III efficacy trial (Protocol 020). Among men who were na&iuml;ve to 14 common HPV types, administration of Gardasil reduced the incidence of external genital lesions caused by vaccine- or non-vaccine HPV types by 81.5 % (95 % CI: 58.0, 93.0). In the Full Analysis Set (FAS) population, the benefit of the vaccine with respect to the overall incidence of EGL was lower, with a reduction of 59.3 % (95 % CI: 40.0, 72.9), as Gardasil does not impact the course of infections or disease that are present at vaccination onset.</p><p>&nbsp;</p><p><u>Impact on Biopsy and Definitive Therapy Procedures</u></p><p>&nbsp;</p><p>The impact of Gardasil on rates of biopsy and treatment of EGL regardless of causal HPV types was evaluated in 2,545 individuals enrolled in Protocol 020. In the HPV na&iuml;ve population (na&iuml;ve to 14 common HPV types), Gardasil reduced the proportion of men who had a biopsy by 54.2 % (95 % CI: 28.3, 71.4) and who were treated by 47.7 % (95 % CI: 18.4, 67.1) at end of study. In the FAS population, the corresponding reduction was 45.7 % (95 % CI: 29.0, 58.7) and 38.1 % (95 % CI: 19.4,</p><p>52.6).</p><p>&nbsp;</p><p><em>Immunogenicity</em></p><p><em>&nbsp;</em></p><p><u>Assays to Measure Immune Response</u></p><p>&nbsp;</p><p>No minimum antibody level associated with protection has been identified for HPV vaccines.</p><p>&nbsp;</p><p>The immunogenicity of Gardasil was assessed in 20,132 (Gardasil n = 10,723; placebo n = 9,409) girls and women 9 to 26 years of age, 5,417 (Gardasil n = 3,109; placebo n = 2,308) boys and men 9 to</p><p>26 years of age and 3,819 women 24 to 45 years of age (Gardasil n = 1,911, placebo n = 1,908).</p><p>&nbsp;</p><p>Type-specific immunoassays, competitive Luminex-based immunoassay (cLIA), with type-specific standards were used to assess immunogenicity to each vaccine type. This assay measures antibodies against a single neutralizing epitope for each individual HPV type.</p><p>&nbsp;</p><p><u>Immune Responses to Gardasil at 1 month post dose 3</u></p><p>&nbsp;</p><p>In the clinical studies in women 16 to 26 years of age, 99.8 %, 99.8 %, 99.8 %, and 99.5 % of individuals who received Gardasil became anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18- seropositive, respectively, by 1 month Postdose 3. In the clinical study in women 24 to 45 years,</p><p>98.4 %, 98.1 %, 98.8 %, and 97.4 % of individuals who received Gardasil became anti-HPV 6, anti- HPV 11, anti-HPV 16, and anti-HPV 18 seropositive, respectively, by 1 month Postdose 3. In the clinical study in men 16 to 26 years, 98.9 %, 99.2 %, 98.8 %, and 97.4 % of individuals who received Gardasil became anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 seropositive, respectively, by 1 month Postdose 3. Gardasil induced high anti-HPV Geometric Mean Titres (GMTs) 1 month Postdose 3 in all age groups tested.</p><p>&nbsp;</p><p>As expected for women 24 to 45 years of age (Protocol 019), the observed antibody titres were lower than that seen in women 16 to 26 years.</p><p>&nbsp;</p><p>Anti-HPV levels in placebo individuals who had cleared an HPV infection (seropositive and PCR</p><p>&nbsp;</p><p>negative) were substantially lower than those induced by the vaccine. Furthermore, anti-HPV levels (GMTs) in vaccinated individuals remained at or above serostatus cut-off during the long-term follow- up of the Phase III studies (see below under <em>Persistence of Immune Response of Gardasil</em>).</p><p>&nbsp;</p><p><u>Bridging the Efficacy of Gardasil from Women to Girls</u></p><p>&nbsp;</p><p>A clinical study (Protocol 016) compared the immunogenicity of Gardasil in 10- to 15-year-old girls to those in 16- to 23 year old women. In the vaccine group, 99.1 to 100 % became seropositive to all vaccine serotypes by 1 month Postdose 3<strong><em>.</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Table 6 compares the 1 month Postdose 3 anti-HPV 6, 11, 16, and 18 GMTs in 9- to 15 year-old girls with those in 16- to 26-year old women.</p><p>&nbsp;</p><p><em>Table 6: Immunogenicity bridging between 9- to 15-year-old girls and 16- to 26-year-old women (per- protocol population) based on titres as measured by cLIA</em></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>9- to 15-Year-Old Girls (Protocols 016 and 018)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>16- to 26-Year-Old Women (Protocols 013 and 015)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>GMT (95</strong><strong> </strong><strong>% CI)</strong></p></td><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>GMT (95</strong><strong> </strong><strong>% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>HPV 6</p></td><td style="vertical-align:top"><p>915</p></td><td style="vertical-align:top"><p>929 (874, 987)</p></td><td style="vertical-align:top"><p>2631</p></td><td style="vertical-align:top"><p>543 (526, 560)</p></td></tr><tr><td style="vertical-align:top"><p>HPV 11</p></td><td style="vertical-align:top"><p>915</p></td><td style="vertical-align:top"><p>1303 (1223, 1388)</p></td><td style="vertical-align:top"><p>2655</p></td><td style="vertical-align:top"><p>762 (735, 789)</p></td></tr><tr><td style="vertical-align:top"><p>HPV 16</p></td><td style="vertical-align:top"><p>913</p></td><td style="vertical-align:top"><p>4909 (4548, 5300)</p></td><td style="vertical-align:top"><p>2570</p></td><td style="vertical-align:top"><p>2294 (2185, 2408)</p></td></tr><tr><td style="vertical-align:top"><p>HPV 18</p></td><td style="vertical-align:top"><p>920</p></td><td style="vertical-align:top"><p>1040 (965, 1120)</p></td><td style="vertical-align:top"><p>2796</p></td><td style="vertical-align:top"><p>462 (444, 480)</p></td></tr></tbody></table><p>GMT- Geometric mean titre in mMU/ml (mMU = milli-Merck units)</p><p>&nbsp;</p><p>Anti-HPV responses at Month 7 among 9- to 15-year-old girls were non-inferior to anti-HPV responses in 16- to 26-year-old women for whom efficacy was established in the Phase III studies. Immunogenicity was related to age and Month 7 anti-HPV levels were significantly higher in younger individuals below 12 years of age than in those above that age.</p><p>&nbsp;</p><p>On the basis of this immunogenicity bridging, the efficacy of Gardasil in 9- to 15-year-old girls is inferred.</p><p>&nbsp;</p><p>In the long-term extension study of Protocol 018, 369 girls 9-15 years old during vaccination with Gardasil in the base study were followed. In the PPE population, no cases of HPV diseases (HPV types 6/11/16/18 related CIN any grade and Genital Warts) were observed through 10.7 years (median follow-up of 10.0 years).</p><p>&nbsp;</p><p><u>Bridging the Efficacy of Gardasil from Men to Boys</u></p><p>&nbsp;</p><p>Three clinical studies (Protocols 016, 018 and 020) were used to compare the immunogenicity of Gardasil in 9- to 15-year-old boys to 16- to 26-year-old men. In the vaccine group, 97.4 to 99.9 % became seropositive to all vaccine serotypes by 1 month Postdose 3<strong><em>.</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Table 7 compares the 1 month Postdose 3 anti-HPV 6, 11, 16, and 18 GMTs in 9- to 15-year-old boys with those in 16- to 26-year-old men.</p><p>&nbsp;</p><p><em>Table 7: Immunogenicity bridging between 9- to 15-year-old boys and 16- to 26-year-old men (per- protocol population) based on titres as measured by cLIA</em></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>9- to 15-Year-Old Boys</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>16- to 26-Year-Old Men</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>GMT (95</strong><strong> </strong><strong>% CI)</strong></p></td><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>GMT (95</strong><strong> </strong><strong>% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>HPV 6</p></td><td style="vertical-align:top"><p>884</p></td><td style="vertical-align:top"><p>1038 (964, 1117)</p></td><td style="vertical-align:top"><p>1093</p></td><td style="vertical-align:top"><p>448 (419, 479)</p></td></tr><tr><td style="vertical-align:top"><p>HPV 11</p></td><td style="vertical-align:top"><p>885</p></td><td style="vertical-align:top"><p>1387 (1299, 1481)</p></td><td style="vertical-align:top"><p>1093</p></td><td style="vertical-align:top"><p>624 (588, 662)</p></td></tr><tr><td style="vertical-align:top"><p>HPV 16</p></td><td style="vertical-align:top"><p>882</p></td><td style="vertical-align:top"><p>6057 (5601, 6549)</p></td><td style="vertical-align:top"><p>1136</p></td><td style="vertical-align:top"><p>2403 (2243, 2575)</p></td></tr><tr><td style="vertical-align:top"><p>HPV 18</p></td><td style="vertical-align:top"><p>887</p></td><td style="vertical-align:top"><p>1357 (1249, 1475)</p></td><td style="vertical-align:top"><p>1175</p></td><td style="vertical-align:top"><p>403 (375, 433)</p></td></tr></tbody></table><p>GMT- Geometric mean titre in mMU/ml (mMU = milli-Merck units)</p><p>&nbsp;</p><p>Anti-HPV responses at Month 7 among 9- to 15-year-old boys were non-inferior to anti-HPV responses in 16- to 26-year-old men for whom efficacy was established in the Phase III studies. Immunogenicity was related to age and Month 7 anti-HPV levels were significantly higher in younger individuals.</p><p>&nbsp;</p><p>On the basis of this immunogenicity bridging, the efficacy of Gardasil in 9- to 15-year-old boys is inferred.</p><p>&nbsp;</p><p>In the long-term extension study of Protocol 018, 326 boys 9-15 years old during vaccination with Gardasil in the base study were followed. In the PPE population, no cases of HPV diseases (HPV types 6/11/16/18 related External Genital Lesions) were observed through 10.6 years (median follow- up of 9.9 years).</p><p>&nbsp;</p><p><u>Persistence of Immune Response of Gardasil</u></p><p>&nbsp;</p><p>A subset of individuals enrolled in the Phase III studies was followed up for a long-term period for safety, immunogenicity and effectiveness. Total IgG Luminex Immunoassay (IgG LIA) was used to assess the persistence of immune response in addition to cLIA.</p><p>&nbsp;</p><p>In all populations (women 9 &ndash; 45 years, men 9 &ndash; 26 years), peak anti-HPV 6, anti-HPV 11, anti- HPV 16, and anti-HPV 18 GMTs cLIA were observed at Month 7. Afterwards, the GMTs declined through Month 24 - 48 and then generally stabilised. The duration of immunity following a 3-dose series has been observed for up to 14 years post-vaccination.</p><p>&nbsp;</p><p>Girls and boys vaccinated with Gardasil at 9-15 years of age in Protocol 018 base study were followed up in an extension study. Depending on HPV type, 60-96 % and 78-98 % of subjects were seropositive by cLIA and IgG LIA respectively 10 years after vaccination (see Table 8).</p><p>&nbsp;</p><p><em>Table 8: Long-term immunogenicity data (per-protocol population) based on percentage of seropositive subjects as measured by cLIA and IgG LIA (Protocol 018) at 10 years, in girls and boys 9-15 years of age</em></p><p><em>&nbsp;</em></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>cLIA</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>IgG LIA</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>% of seropositive subjects</strong></p></td><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>% of seropositive subjects</strong></p></td></tr><tr><td style="vertical-align:top"><p>HPV 6</p></td><td style="vertical-align:top"><p>409</p></td><td style="vertical-align:top"><p>89 %</p></td><td style="vertical-align:top"><p>430</p></td><td style="vertical-align:top"><p>93 %</p></td></tr><tr><td style="vertical-align:top"><p>HPV 11</p></td><td style="vertical-align:top"><p>409</p></td><td style="vertical-align:top"><p>89 %</p></td><td style="vertical-align:top"><p>430</p></td><td style="vertical-align:top"><p>90 %</p></td></tr><tr><td style="vertical-align:top"><p>HPV 16</p></td><td style="vertical-align:top"><p>403</p></td><td style="vertical-align:top"><p>96 %</p></td><td style="vertical-align:top"><p>426</p></td><td style="vertical-align:top"><p>98 %</p></td></tr><tr><td style="vertical-align:top"><p>HPV 18</p></td><td style="vertical-align:top"><p>408</p></td><td style="vertical-align:top"><p>60 %</p></td><td style="vertical-align:top"><p>429</p></td><td style="vertical-align:top"><p>78 %</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p>Women vaccinated with Gardasil at 16-23 years of age in Protocol 015 base were followed up in an extension study. Fourteen years after vaccination, 91 %, 91 %, 98 % and 52 % were anti-HPV 6, anti- HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the cLIA, respectively, and 98 %, 98 %, 100 % and 94 % were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the IgG LIA, respectively.</p><p>&nbsp;</p><p>Women vaccinated with Gardasil at 24-45 years of age in Protocol 019 base study were followed up in an extension study. Ten years after vaccination, 79 %, 85 %, 94 %, and 36 % were anti-HPV 6, anti- HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the cLIA, respectively, and 86 %, 79 %, 100 % and 83 % were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the IgG LIA, respectively.</p><p>&nbsp;</p><p>Men vaccinated with Gardasil at 16-26 years of age in Protocol 020 base study were followed up in an extension study. Ten years after vaccination, 79 %, 80 %, 95 % and 40 % were anti-HPV 6, anti-</p><p>HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the cLIA, respectively, and 92 %, 92 %, 100 %</p><p>&nbsp;</p><p>and 92 % were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the IgG LIA, respectively.</p><p>&nbsp;</p><p>In these studies, individuals who were seronegative for anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 in the cLIA were still protected against clinical disease after a follow-up of 14 years for 16-23 year-old women, 10 years for 24-45 year-old women, and 10 years for 16-26 year-old men.</p><p>&nbsp;</p><p><u>Evidence of Anamnestic (Immune Memory) Response</u></p><p>&nbsp;</p><p>Evidence of an anamnestic response was seen in vaccinated women who were seropositive to relevant HPV type(s) prior to vaccination. In addition, a subset of vaccinated women who received a challenge dose of Gardasil 5 years after the onset of vaccination, exhibited a rapid and strong anamnestic response that exceeded the anti-HPV GMTs observed 1 month Postdose 3.</p><p>&nbsp;</p><p><u>HIV infected subjects</u></p><p>&nbsp;</p><p>An academic study documenting safety and immunogenicity of Gardasil has been performed in 126 HIV infected subjects aged from 7-12 years (of which 96 received Gardasil). Seroconversion to all four antigens occurred in more than ninety-six percent of the subjects. The GMTs were somewhat lower than reported in non-HIV infected subjects of the same age in other studies. The clinical relevance of the lower response is unknown. The safety profile was similar to non-HIV infected subjects in other studies. The CD4 % or plasma HIV RNA was not affected by vaccination.</p><p>&nbsp;</p><p><u>Immune Responses to Gardasil using a 2-dose schedule in individuals 9-13 years of age</u></p><p>&nbsp;</p><p>A clinical trial showed that among girls who received 2 doses of HPV vaccine 6 months apart, antibody responses to the 4 HPV types, one month after the last dose were non-inferior to those among young women who received 3 doses of the vaccine within 6 months.</p><p>&nbsp;</p><p>At Month 7, in the Per Protocol population, the immune response in girls aged 9-13 years (n = 241) who received 2 doses of Gardasil (at 0, 6 months) was non&ndash;inferior and numerically higher to the immune response in women aged 16-26 years (n = 246) who received 3 doses of Gardasil (at 0, 2, 6 months).</p><p>&nbsp;</p><p>At 36 month follow-up, the GMT in girls (2 doses, n = 86) remained non-inferior to the GMT in women (3 doses, n = 86) for all 4 HPV types.</p><p>&nbsp;</p><p>In the same study, in girls aged 9-13 years, the immune response after a 2-dose schedule was numerically lower than after a 3-dose schedule (n = 248 at Month 7; n = 82 at Month 36). The clinical relevance of these findings is unknown.</p><p>&nbsp;</p><p>Post hoc analyses were conducted at 120‑month follow-up in girls (2 doses, n&nbsp;=&nbsp;35; 3 doses, n&nbsp;=&nbsp;38) and women (3 doses, n&nbsp;=&nbsp;30). The GMT ratios (girls who received 2 doses / women who received 3 doses) ranged from 0.99 to 2.02 for all 4 HPV types. The GMT ratios (girls who received 2 doses / girls who received 3 doses) ranged from 0.72 to 1.21 for all 4 HPV types. The lower bound of the 95&nbsp;% CI of all the GMT ratios remained &gt;&nbsp;0.5 through month 120 (except for HPV&nbsp;18 in girls who received 2&nbsp;doses / girls who received 3&nbsp;doses).</p><p>&nbsp;</p><p>Seropositivity rates in girls and women were &gt;&nbsp;95&nbsp;% for HPV&nbsp;6, 11, and 16, and seropositivity rates for HPV&nbsp;18 were &gt;&nbsp;80&nbsp;% in girls who received.2&nbsp;doses, &gt;&nbsp;90&nbsp;% in girls who received 3&nbsp;doses, and &gt;&nbsp;60&nbsp;% in women who received 3&nbsp;doses, in the cLIA.</p><p>&nbsp;</p><p><u>Prevention of juvenile-onset recurrent respiratory papillomatosis (JoRRP) by vaccination of girls and women of childbearing potential</u></p><p>JoRRP is caused by upper airway infection primarily with HPV types 6 and 11, acquired vertically (mother-to-child) during childbirth. Observational studies in the US and Australia have shown that the introduction of Gardasil since 2006 has led to declines in the incidence of JoRRP at population level.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single-dose and repeated-dose toxicity and local tolerance studies revealed no special hazards to humans.</p><p>&nbsp;</p><p>Gardasil induced specific antibody responses against HPV types 6, 11, 16, and 18 in pregnant rats, following one or multiple intramuscular injections. Antibodies against all four HPV types were transferred to the offspring during gestation and possibly during lactation. There were no treatment- related effects on developmental signs, behaviour, reproductive performance, or fertility</p><p>of the offspring.</p><p>&nbsp;</p><p>GARDASIL administered to male rats at the full human dose (120 mcg total protein) had no effects on reproductive performance including fertility, sperm count, and sperm motility, and there were no vaccine-related gross or histomorphologic changes on the testes and no effects on testes weights.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride (9.56 mg)</p><p>L-histidine (0.78 mg)</p><p>Polysorbate 80 (50 &mu;g)</p><p>Sodium borate (35 &mu;g)</p><p>Water for injections (QS)</p><p>&nbsp;</p><p>&nbsp;</p><p>For adjuvant, see section 2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Gardasil, suspension for injection in a pre-filled syringe :</u></p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>&nbsp;</p><p>Do not freeze. Keep the pre-filled syringe in the outer carton in order to protect from light. Gardasil should be administered as soon as possible after being removed from the refrigerator.</p><p>Data from stability studies demonstrate that the vaccine components are stable for 96 hours when stored at temperatures from 8&deg;C to &deg; 40 C. At the end of this period Gardasil should be used or discarded. These data are intended to guide healthcare professionals in case of temporary temperature excursion only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Gardasil, suspension for injection in a pre-filled syringe :</u></p><p>&nbsp;</p><p>0.5 ml suspension in a pre-filled syringe (glass) with plunger stopper (siliconized FluroTec-coated bromobutyl elastomer or non-coated chlorobutyl elastomer) and a tip cap (bromobutyl ) without needle or with one or two needle(s) - pack size of 1, 10 or 20.</p><p>&nbsp;</p><p>Not all pack sizes are marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Gardasil, suspension for injection in a pre-filled syringe:</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gardasil may appear as a clear liquid with a white precipitate prior to agitation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shake well before use, the pre-filled syringe, to make a suspension. After thorough agitation, it is a white, cloudy liquid.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inspect the suspension visually for particulate matter and discolouration prior to administration.</p><p>Discard the vaccine if particulates are present and/or if it appears discoloured.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Two needles of different lengths are provided in the pack, choose the appropriate needle to ensure an intramuscular (IM) administration depending on your patient&rsquo;s size and weight.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Attach the needle by twisting in a clockwise direction until the needle fits securely on the syringe. Administer the entire dose as per standard protocol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inject immediately using the intramuscular (IM) route, preferably in the deltoid area of the upper arm or in the higher anterolateral area of the thigh.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The vaccine should be used as supplied. The full recommended dose of the vaccine should be used.</p><p>&nbsp;</p><p>Any unused vaccine or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder:
Merck Sharp & Dohme B.V.,
Waarderweg 39 ,2031 BN Haarlem,
P.O.Box 581, 2003 Haarlem, the Netherlands

Manufacturer:
Merck, Sharp & Dohme LLC
770 Sumneytown Pike, West Point, PA 19486, US.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oct 2024

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>